Podcasts about Harvard Medical School

On 28 September 2024, a conversation between Dr. Vivek Murthy, MD, US Surgeon General, and Sadhguru where they will explore "Loneliness: In is the Only Way Out". Hosted at the Joseph B. Martin Conference Room, Harvard Medical School, Boston, the session will be moderated by Bala Subramaniam, MD, MPH, Director of Sadhguru Center for a Conscious Planet. Set the context for a joyful, exuberant day with a short, powerful message from Sadhguru. Explore a range of subjects with Sadhguru, discover how every aspect of life can be a stepping stone, and learn to make the most of the potential that a human being embodies.  Conscious Planet: ⁠https://www.consciousplanet.org⁠ Sadhguru App (Download): ⁠https://onelink.to/sadhguru__app⁠ Official Sadhguru Website: ⁠https://isha.sadhguru.org⁠ Sadhguru Exclusive: ⁠https://isha.sadhguru.org/in/en/sadhguru-exclusive⁠ Inner Engineering Link: isha.co/ieo-podcast Yogi, mystic and visionary, Sadhguru is a spiritual master with a difference. An arresting blend of profundity and pragmatism, his life and work serves as a reminder that yoga is a contemporary science, vitally relevant to our times. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week we review the topic of mitral annular disjunction ("MAD") and the possible association with ventricular arrhythmia or sudden death in the connective tissue disease patient. Is there a 'cut off' distance above which patients deserve more significant arrhythmia surveillance? What is the best way to measure the MAD distance? Can patients with low MAD distances have lower degrees or even no arrhythmic surveillance? How often should this distance be measured on CMR and can an echo measurement provide similar data? Dr. Daniel Castellanos, the first author of this work and Assistant Professor of Pediatrics at Harvard Medical School shares his deep insights this week.DOI: 10.1016/j.jocmr.2025.101954

On 28 September 2024, a conversation between Dr. Vivek Murthy, MD, US Surgeon General, and Sadhguru where they will explore "Loneliness: In is the Only Way Out". Hosted at the Joseph B. Martin Conference Room, Harvard Medical School, Boston, the session will be moderated by Bala Subramaniam, MD, MPH, Director of Sadhguru Center for a Conscious Planet. Set the context for a joyful, exuberant day with a short, powerful message from Sadhguru. Explore a range of subjects with Sadhguru, discover how every aspect of life can be a stepping stone, and learn to make the most of the potential that a human being embodies.  Conscious Planet: ⁠https://www.consciousplanet.org⁠ Sadhguru App (Download): ⁠https://onelink.to/sadhguru__app⁠ Official Sadhguru Website: ⁠https://isha.sadhguru.org⁠ Sadhguru Exclusive: ⁠https://isha.sadhguru.org/in/en/sadhguru-exclusive⁠ Inner Engineering Link: isha.co/ieo-podcast Yogi, mystic and visionary, Sadhguru is a spiritual master with a difference. An arresting blend of profundity and pragmatism, his life and work serves as a reminder that yoga is a contemporary science, vitally relevant to our times. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Dementia Researcher - Xxplored Women's Brain Health podcast, host Dr Laura Stankeviciute speaks with Professor Claudia Barth from Charite University and Dr Gillian Coughlan from Harvard Medical School to examine the midlife transition, menopause and its significance for women's brain health. Together they outline what the menopause truly involves across the early, late, and post stages, and explain how hormonal change affects brain structure, energy use, mood, and cognition. They also explore why this period may coincide with greater vulnerability to later Alzheimer's disease and discuss the role of early or surgical menopause, symptom severity, and gaps in existing research cohorts. The episode highlights the need for richer reproductive data, real time biomarker studies, and closer collaboration with digital health tools to better capture women's lived experiences. It reflects a growing wave of research and public interest aimed at improving understanding, support, and evidence based care during this important life stage. -- Takeaways ● Menopause is a long transition shaped by fluctuating hormones. ● Cognitive and mood symptoms reflect changes in brain networks. ● Earlier menopause is linked with increased later Alzheimer's risk. ● Major research cohorts lack detailed reproductive data. ● New real time studies are beginning to track symptoms and biomarkers. ● Digital tools will be key for future research. ● Better global representation is needed across studies. ● Momentum is building to close long standing gaps in women's health. -- Find bios on all our speakers, a full transcript of the show and more on our website at https://www.dementiaresearcher.nihr.ac.uk - Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://www.bsky.app/profile/dementiare…archer.bsky.social -- Download and Register with our Community App: https://www.onelink.to/dementiaresearcher -- Chapters 00:00 Introduction to Menopause and Research Focus 07:25 Understanding Menopause: Definitions and Stages 16:27 Menopause and Alzheimer's Disease: A Critical Connection 22:43 Understanding Menopause and Brain Health 25:21 Historical Blind Spots in Alzheimer's Research 26:38 The Importance of Reproductive Variables 31:46 Biomarkers and Methodologies in Women's Health Research 35:28 Industry Collaboration in Research 39:00 Personal Reflections on Women's Brain Health

Episode 225 - In The Shadow of Silence, A Novel About the Ripple Effects of Depression on Those Around UsAbout the authorRaymonde Dumont, MD, LMFT, is a pediatrician as well as a family therapist. She practiced and taught for several years at Harvard Medical School, and at the Joslin Diabetes Center. Her work focused on the effects of a person's illness through their entire family. She showed that mental health and family function affect the medical outcome. In her private practiceas a family therapist, she helps families to navigate difficulties by collaborating, rather than becoming divided.She is also a mother, a widow, and a friend to many. She now turns her years of experience into words that speak of resilience, and of the flawed road that leads us to becoming good enough. She wrote this book because the story would not let her go, and because she hopes it will bring a little insight and comfort.She has published many professional articles, but in fiction, she finds a more personal, intimate voice. Her short stories have been published in Persimmon Tree and in The Hemlock Journal. You can find her blog on Substack as raedumont.substack. Or you can contact her through her website at Rae Dumont, Writer.She lives and practices in Montclair, New Jersey, within reach of New York City.In the Shadow of Silence: A Novel A novel that follows the pursuit of love and joy—until the descent of untreated depression ends with unbearable loss, forcing a family to deal with the shocking and immediate aftermath of suicide.Eva's lonely childhood has given her an intuitive connection with kids and teenagers. She is a gifted child psychiatrist. Single, she dreams of having her own children, and she yearns for love. The future seems bright when she meets Lyman; They build a family. They share adventures. They meet life's challenges as team. They navigate a bout of Lyman's depression; treatment works.They share rich, fulfilling years while their careers develop, and their children grow up.When their sons enter adulthood and their daughter is a teenager, they plan an entire summer as a family. But Lyman abruptly stops both therapy and medication. He spirals into a dark and irritable isolation that none of them can penetrate.After his brutal suicide, Eva is left to cope and to guide her children through the trauma, as they each rebuild their lives.https://www.raedumontwriting.org/___https://dadspace.camusic provided by Blue Dot SessionsSong: The Big Ten https://app.sessions.blue/browse/track/258270

Many diets claim to be good for you. But the Mediterranean diet rises to the top with its research-proven benefits: it's been shown to increase life expectancy; decrease risk for dementia; improve mental health and cognitive function; and lower the risk of heart disease for nearly every demographic. What is it that makes the diet so great? In this episode, host Samantha Laine Perfas discuss the Mediterranean diet with nutritional psychiatrist Uma Naidoo and Mediterranean diet expert Miguel Ángel Martínez-González about how people can make nutritional changes that work for them day to day.

Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas"  Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO PO and an Associate Professor at the OU Health Stephenson Cancer Center. Today, I'm excited to be joined by Dr. Jessica Ross, third-year medical oncology fellow at the Memorial Sloan Kettering Cancer Center, as well as Dr. Alissa Cooper, thoracic medical oncologist at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School. Both are first and last authors of the JCO Precision Oncology article entitled "Clinical and Pathologic Landscapes of Delta-like Ligand 3 and Seizure-Related Homolog Protein 6 or SEZ6 Protein Expression in Neuroendocrine Carcinomas." At the time of this recording, our guest disclosures will be linked in the transcript. Jessica and Alissa, welcome to our podcast, and thank you for joining us today. Dr. Jessica Ross: Thanks very much for having us. Dr. Alissa Cooper: Thank you. Excited to be here. Dr. Rafeh Naqash: It's interesting, a couple of days before I decided to choose this article, one of my GI oncology colleagues actually asked me two questions. He said, "Rafeh, do you know how you define DLL3 positivity? And what is the status of DLL3 positivity in GI cancers, GI neuroendocrine carcinomas?" The first thing I looked up was this JCO article from Martin Wermke. You might have seen it as well, on obrixtamig, a phase 1 study, a DLL3 bi-specific T-cell engager. And they had some definitions there, and then this article came along, and I was really excited that it kind of fell right in place of trying to understand the IHC landscape of two very interesting targets. Since we have a very broad and diverse audience, especially community oncologists, trainees, and of course academic clinicians and some people who are very interested in genomics, we'll try to make things easy to understand. So my first question for you, Jessica, is: what is DLL3 and SEZ6 and why are they important in neuroendocrine carcinomas? Dr. Jessica Ross: Yeah, good question. So, DLL3, or delta-like ligand 3, is a protein that is expressed preferentially on the tumor cell surface of neuroendocrine carcinomas as opposed to normal tissue. It is a downstream target of ASCL1, and it's involved in neuroendocrine differentiation, and it's an appealing drug target because it is preferentially expressed on tumor cell surfaces. And so, it's a protein, and there are several drugs in development targeting this protein, and then Tarlatamab is an approved bi-specific T-cell engager for the treatment of extensive-stage small cell lung cancer in the second line. SEZ6, or seizure-like homolog protein 6, is a protein also expressed on neuroendocrine carcinoma cell surface. Interestingly, so it's expressed on neuronal cells, but its exact role in neuroendocrine carcinomas and oncogenesis is actually pretty poorly understood, but it was identified as an appealing drug target because, similarly to DLL3, it's preferentially expressed on the tumor cell surface. And so this has also emerged as an appealing drug target, and there are drugs in development, including antibody-drug conjugates, targeting this protein for that reason. Dr. Alissa Cooper: Over the last 10 to 15 years or so, there's been an increasing focus on precision oncology, finding specific targets that actually drive the cancer to grow, not just within lung cancer but in multiple other primary cancers. But specifically, at least speaking from a thoracic oncology perspective, the field of non-small cell lung cancer has completely exploded over the past 15 years with the discovery of driver oncogenes and then matched targeted therapies. Within the field of neuroendocrine carcinomas, including small cell lung cancer but also other high-grade neuroendocrine carcinomas, there has not been the same sort of progress in terms of identifying targets with matched therapies. And up until recently, we've sort of been treating these neuroendocrine malignancies kind of as a monolithic disease process. And so recently, there's been sort of an explosion of research across the country and multiple laboratories, multiple people converging on the same open questions about why might patients with specific tumor biologies have different kind of responses to different therapies. And so first this came from, you know, why some patients might have a good response to chemo and immunotherapy, which is the first-line approved therapy for small cell lung cancer, and we also sort of extrapolate that to other high-grade neuroendocrine carcinomas. What's the characteristic of that tumor biology? And at the same time, what are other targets that might be identifiable? Just as Jesse was saying, they're expressed on the cell surface, they're not necessarily expressed in normal tissue. Might this be a strategy to sort of move forward and create smarter therapies for our patients and therefore move really into a personalized era for treatment for each patient? And that's really driving, I think, a lot of the synthesis of this work of not only the development of multiple new therapies, but really understanding which tumor might be the best fit for which therapy. Dr. Rafeh Naqash: Thank you for that explanation, Alissa. And as you mentioned, these are emerging targets, some more further along in the process with approved drugs, especially Tarlatamab. And obviously, DLL3 was something identified several years back, but drug development does take time, and readout for clinical trials takes time. Could you, for the sake of our audience, try to talk briefly about the excitement around Tarlatamab in small cell lung cancer, especially data that has led to the FDA approval in the last year, year and a half? Dr. Alissa Cooper: Sure. Yeah, it's really been an explosion of excitement over, as you're saying, the last couple of years, and work really led by our mentor, Charlie Rudin, had identified DLL3 as an exciting target for small cell lung cancer specifically but also potentially other high-grade neuroendocrine malignancies. Tarlatamab is a DLL3-targeting bi-specific T-cell engager, which targets DLL3 on the small cell lung cancer cells as well as CD3 on T cells. And the idea is to sort of introduce the cancer to the immune system, circumventing the need for MHC class antigen presentation, which that machinery is typically not functional in small cell lung cancer, and so really allowing for an immunomodulatory response, which had not really been possible for most patients with small cell lung cancer prior to this. Tarlatamab was tested in a phase 2 registrational trial of about 100 patients and demonstrated a response rate of 40%, which was very exciting, especially compared with other standard therapies which were available for small cell lung cancer, which are typically cytotoxic therapies. But most excitingly, more than even the response rate, I think, in our minds was the durability of response. So patients whose disease did have a response to Tarlatamab could potentially have a durable response lasting a number of months or even over a year, which had previously not ever been seen in this in the relapsed/refractory setting for these patients. I think the challenge with small cell lung cancer and other high-grade neuroendocrine malignancies is that a response to therapy might be a bit easier to achieve, but it's that durability. The patient's tumors really come roaring back quite aggressively pretty quickly. And so this was sort of the most exciting prospect is that durability of response, that long potential overall survival tail of the curve really being lifted up. And then most recently at ASCO this year, Dr. Rudin presented the phase 3 randomized controlled trial which compared Tarlatamab to physician's choice of chemotherapy in a global study. And the choice of chemotherapy did vary depending on the part of the world that the patients were enrolled in, but in general, it was a really markedly positive study for response rate, for progression-free survival, and for overall survival. Really exciting results which really cemented Tarlatamab's place as the standard second-line therapy for patients with small cell lung cancer whose disease has progressed on first-line chemo-immunotherapy. So that has been very exciting. This drug was FDA approved in May of 2024, and so has been used extensively since then. I think the adoption has been pretty widespread, at least in the US, but now in this global trial that was just presented, and there was a corresponding New England Journal paper, I think really confirms that this is something we really hopefully can offer to most of our patients. And I think, as we all know, that this therapy or other therapies like it are also being tested potentially in the first-line setting. So there was data presented with Tarlatamab incorporated into the maintenance setting, which also showed exciting results, albeit in a phase 1 trial, but longer overall survival than we're used to seeing in this patient population. And we await results of the study that is incorporating Tarlatamab into the induction phase with chemotherapy as well. So all of this is extraordinarily exciting for our patients to sort of move the needle of how many patients we can keep alive, feeling functional, feeling well, for as long as possible. Dr. Rafeh Naqash: Very exciting session at ASCO. I was luckily one of the co-chairs for the session that Dr. Rudin presented it, and I remember somebody mentioning there was more progress seen in that session for small cell lung cancer than the last 30, 35 years for small cell, very exciting space and time to be in as far as small cell lung cancer. Now going to this project, Jessica, since you're the first author and Alissa's the last, I'm assuming there was a background conversation that you had with Alissa before you embarked on this project as an idea. So could you, again, for other trainees who are interested in doing research, and it's never easy to do research as a resident and a fellow when you have certain added responsibilities. Could you give us a little bit of a background on how this started and why you wanted to look at this question? Dr. Jessica Ross: Yeah, sure. So, as with many exciting research concepts, I think a lot of them are derived from the clinic. And so I think Alissa and I both see a good number of patients with small cell, large cell lung cancer, and then high-grade neuroendocrine carcinomas. And so I think this was really born out of a basic conversation of we have these drugs in development targeting these two proteins, DLL3 and SEZ6, but really what is the landscape of cancers that express these proteins and who are the patients that really might benefit from these exciting new therapies. And of course, there was some data out there, but sort of less than one would imagine in terms of, you know, neuroendocrine carcinomas can really come from anywhere in the body. And so when you're seeing a patient with small cell of the cervix, for example, like what are the chances that their cancer expresses DLL3 or expresses SEZ6? So it was really derived from this pragmatic, clinically oriented question that we had both found ourselves thinking about, and we were lucky enough at MSK, we had started systematically staining patients' tumors for DLL3, tumors that are high-grade neuroendocrine carcinomas, and then we had also more recently started staining for SEZ6 as well. And so we had this nice prospectively collected dataset with which to answer this question. Dr. Rafeh Naqash: Excellent. And Alissa, could you try to go into some of the details around which patients you chose, how many patients, what was the approach that you selected to collect the data for this project? Dr. Alissa Cooper: This is perhaps a strength but also maybe a limitation of this dataset is, as Jesse alluded to, our pathology colleagues are really the stars of this paper here because we were lucky enough at MSK that they were really forethinking. They are absolute experts in the field and really forward-thinking people in terms of what information might be needed in the future to drive treatment decision-making. And so, as Jesse had said, small cell lung cancer tumor samples reflexively are stained for DLL3 and SEZ6 at MSK if there's enough tumor tissue. The other high-grade neuroendocrine carcinomas, those stains are performed upon physician request. And so that is a bit of a mixed bag in terms of the tumor samples we were able to include in this dataset because, you know, upon physician request depends on a number of factors, but actually at MSK, a number of physicians were requesting these stains to be done on their patients with high-grade neuroendocrine cancers of of other histologies. So we looked at all tumor samples with a diagnosis of high-grade neuroendocrine carcinoma of any histology that were stained for these two stains of interest. You know, I can let Jesse talk a bit more about the methodology. She was really the driver of this project. Dr. Jessica Ross: Yeah, sure. So we had 124 tumor samples total. All of those were stained for DLL3, and then a little less than half, 53, were stained for SEZ6. As Alissa said, they were from any primary site. So about half of them were of lung origin, that was the most common primary site, but we included GI tract, head and neck, GU, GYN, even a few tumors of unknown origin. And again, that's because I think a lot of these trials are basket trials that are including different high-grade neuroendocrine carcinomas no matter the primary site. And so we really felt like it was important to be more comprehensive and inclusive in this study. And then, methodologically, we also defined positivity in terms of staining of these two proteins as anything greater than or equal to 1% staining. There's really not a defined consensus of positivity when it comes to these two novel targets and staining for these two proteins. But in the Tarlatamab trials, for some of the correlative work that's been done, they use that 1% cutoff, and we just felt like being consistent with that and also using a sort of more pragmatic yes/no cutoff would be more helpful for this analysis. Dr. Alissa Cooper: And that was a point of discussion, actually. We had contemplated multiple different schemas, actually, for how to define thresholds of positivity. And I know you brought up that question before, what does it mean to be DLL3 positive or DLL3 high? I think you were alluding to prior that there was a presentation of obrixtamig looking at extra-pulmonary neuroendocrine carcinomas, and they actually divvied up the results between DLL3 50% or greater versus DLL3 low under 50%. And they actually did demonstrate differential efficacy certainly, but also some differential safety as well, which is very provocative and that kind of analysis has not been presented for other novel therapies as far as I'm aware. I could be wrong, but as far as I'm aware, that was sort of the first time that we saw a systematic presentation of considering patients to be, quote unquote, "high" or "low" in these sort of novel targets. I think it is important because the label for Tarlatamab does not require any DLL3 expression at all, actually. So it's not hinging upon DLL3 expression. They depend on the fact that the vast majority of small cell lung cancer tumors do express DLL3, 85% to 90% is what's been demonstrated in a few studies. And so, there's not prerequisite testing needed in that regard, but maybe for these extra-pulmonary, other histology neuroendocrine carcinomas, maybe it does matter to some degree. Dr. Rafeh Naqash: Definitely agree that this evolving landscape of trying to understand whether an expression for something actually really does correlate with, whether it's an immune cell engager or an antibody-drug conjugate is a very evolving and dynamically moving space. And one of the questions that I was discussing with one of my friends was whether IHC positivity and the level of IHC positivity, as you've shown in one of those plots where you have double positive here on the right upper corner, you have the double negative towards the left lower, whether that somehow determines mRNA expression for DLL3. Obviously, that was not the question here that you were looking at, but it does kind of bring into question certain other aspects of correlations, expression versus IHC. Now going to the figures in this manuscript, very nicely done figures, very easy to understand because I've done the podcast for quite a bit now, and usually what I try to do first is go through the figures before I read the text, and and a lot of times it's hard to understand the figures without reading the text, but in your case, specifically the figures were very, very well done. Could you give us an overview, a quick overview of some of the important results, Jessica, as far as what you've highlighted in the manuscript? Dr. Jessica Ross: Sure. So I think the key takeaway is that, of the tumors in our cohort, the majority were positive for DLL3 and positive for SEZ6. So about 80% of them were positive for DLL3 and 80% were positive for SEZ6. About half of the tumors were stained for both proteins, and about 65% of those were positive as well. So I think if there's sort of one major takeaway, it's that when you're seeing a patient with a high-grade neuroendocrine carcinoma, the odds are that their tumor will express both of these proteins. And so that can sort of get your head thinking about what therapies they might be eligible for. And then we also did an analysis of some populations of interest. So for example, we know that non-neuroendocrine pathologies can transform into neuroendocrine tumors. And so we specifically looked at that subset of patients with transformed tumors, and those were also- the majority of them were positive, about three-quarters of them were positive for both of these two proteins. We looked at patients with brain met samples, again, about 70% were positive. And then I'd say the last sort of population of interest was we had a subset of 10 patients who had serial biopsies stained for either DLL3 or SEZ6 or both. In between the two samples, these patients were treated with chemotherapy. They were not treated with targeted therapy, but interestingly, in the majority of cases, the testing results were concordant, meaning if it was DLL3 positive to begin with, it tended to remain DLL3 positive after treatment. And so I think that's important as well as we think about, you know, a patient who maybe had DLL3 testing done before they received their induction chemo-IO, we can somewhat confidently say that they're probably still DLL3 positive after that treatment. And then finally, we did do a survival analysis among specifically the patients with lung neuroendocrine carcinomas. We looked at whether DLL3 expression affected progression-free survival on first-line platinum-etoposide, and then we looked at did it affect overall survival. And we found that it did not have an impact or the median progression-free survival was similar whether you were DLL3 positive or negative. But interestingly, with overall survival, we found that DLL3 positivity actually correlated with slightly improved overall survival. These were small numbers, and so, you know, I think we have to interpret this with caution, for sure, but it is interesting. I think there may be something to the fact that five of the patients who were DLL3 positive were treated with DLL3-targeting treatments. And so this made me think of, like in the breast cancer world, for example, if you have a patient with HER2-positive disease, it initially portended worse prognosis, more aggressive disease biology, but on the other hand, it opens the door for targeted treatments that actually now, at least with HER2-positive breast cancer, are associated with improved outcomes. And so I think that's one finding of interest as well. Dr. Rafeh Naqash: Definitely proof-of-concept findings here that you guys have in the manuscript. Alissa, if I may ask you, what is the next important step for a project like this in your mind? Dr. Alissa Cooper: Jesse has highlighted a couple of key findings that we hope to move forward with future investigative studies, not necessarily in a real-world setting, but maybe even in clinical trial settings or in collaboration with sponsors. Are these biomarkers predictive? Are they prognostic? You know, those are still- we have some nascent data, data has been brewing, but I think that we we still don't have the answers to those open questions, which I think are critically important for determining not only clinical treatment decision-making, but also our ability to understand sequencing of therapies, prioritization of therapies. I think a prospective, forward-looking project, piggybacking on that paired biopsy, you know, we had a very small subset of patients with paired biopsies, but a larger subset or cohort looking at paired biopsies where we can see is there evolution of these IHC expression, even mRNA expression, as you're saying, is there differential there? Are there selection pressures to targeted therapies? Is there upregulation or downregulation of targets in response not just to chemotherapy, but for example, for other sort of ADCs or bi-specific T-cell engagers? I think those are going to be critically important future studies which are going to be a bit challenging to do, but really important to figure out this key clinical question of sequencing, which we're all contemplating in our clinics day in and day out. If you have a patient, and these patients often can be sick quite quickly, they might have one shot of what's the next treatment that you're going to pick. We can't guarantee that every patient is going to get to see every therapy. How can you help to sort of answer the question of like what should you offer? So I think that's the key question sort of underlying any future work is how predictive or prognostic are these biomarkers? What translational or correlative studies can we do on the tissue to understand clinical treatment decision-making? I think those are the key things that will unfold in the next couple of years. Dr. Rafeh Naqash: The last question for you, Alissa, that I have is, you are fairly early in your career, and you've accomplished quite a lot. One of the most important things that comes out from this manuscript is your mentorship for somebody who is a fellow and who led this project. For other junior investigators, early-career investigators, how did you do this? How did you manage to do this, and how did you mentor Jessica on this project with some of the lessons that you learned along the way, the good and other things that would perhaps help other listeners as they try to mentor residents, trainees, which is one of the important things of what we do in our daily routine? Dr. Alissa Cooper: I appreciate you calling me accomplished. Um, I'm not sure how true that is, but I appreciate that. I didn't have to do a whole lot with this project because Jesse is an extraordinarily smart, driven, talented fellow who came up with a lot of the clinical questions and a lot of the research questions as well. And so this project was definitely a collaborative project on both of our ends. But I think what was helpful from both of our perspectives is from my perspective, I could kind of see that this was a gap in the literature that really, I think, from my work leading clinical trials and from treating patients with these kinds of cancers that I really hoped to answer. And so when I came to Jessica with this idea as sort of a project to complete, she was very eager to take it and run with it and also make it her own. You know, in terms of early mentorship, I have to admit this was the first project that I mentored, so it was a great learning experience for me as well because as an early-career clinician and researcher, you're used to having someone else looking over your shoulder to tell you, "Yes, this is a good journal target, here's what we can anticipate reviewers are going to say, here are other key collaborators we should include." Those kind of things about a project that don't always occur to you as you're sort of first starting out. And so all of that experience for me to be identifying those more upper-level management sort of questions was a really good learning experience for me. And of course, I was fantastically lucky to have a partner in Jesse, who is just a rising star. Dr. Jessica Ross: Thank you. Dr. Rafeh Naqash: Well, excellent. It sounds like the first of many other mentorship opportunities to come for you, Alissa. And Jessica, congratulations on your next step of joining and being faculty, hopefully, where you're training. Thank you again, both of you. This was very insightful. I definitely learned a lot after I reviewed the manuscript and read the manuscript. Hopefully, our listeners will feel the same. Perhaps we'll have more of your work being published in JCO PO subsequently. Dr. Alissa Cooper: Hope so. Thank you very much for the opportunity to chat today. Dr. Jessica Ross: Yes, thank you. This was great. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so as you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Disclosures: Dr. Alissa Jamie Cooper Honoraria Company: MJH Life Scienes, Ideology Health, Intellisphere LLC, MedStar Health, Physician's Education Resource, LLC,  Gilead Sciences, Regeneron, Daiichi Sankyo/Astra Zeneca, Novartis,  Research Funding: Merck, Roche, Monte Rosa Therapeutics, Abbvie, Amgen, Daiichi Sankyo/Astra Zeneca Travel, Accommodations, Expenses: Gilead Sciences

Pre-Order The Forever Strong PLAYBOOK and receive exclusive bonuses: https://drgabriellelyon.com/playbook/Want ad-free episodes, exclusives and access to community Q&As? Subscribe to Forever Strong Insider: https://foreverstrong.supercast.comIn this compilation episode, Dr. Gabrielle Lyon is joined by the top experts in Testosterone and men's health treatments. You'll learn:Why aging alone doesn't drop T levels and why acquisition of conditions like obesity is the real culprit.Why the standard "low T" cutoff is misleading and why you must check your Free Testosterone.How erectile dysfunction is a sensitive marker of overall health and heart risk.The efficacy of Cialis/Viagra for both erections and cardiac protection, and the risks of unchecked influencer advice on steroids.The direct link between muscle mass, exercise, and sexual function—and why the penis is the "first to go" when overall health declines.Chapter Markers:0:00 - Testosterone is a Brain Hormone0:40 - Debunking the Myth: Male Menopause (Andropause) Doesn't Exist1:33 - The Dangers of Unchecked Influencer Advice on Testosterone3:07 - Defining Testosterone Deficiency: Symptoms vs. Signs5:10 - The Arbitrary Number: Why Guidelines Disagree on Low T8:29 - Free Testosterone: The Most Reliable Indicator of Male Health15:28 - TRT vs. Steroids: Defining the Line and Risks18:59 - The Real Risks of TRT: Infertility and Hematocrit22:36 - The Shocking Backstory: Challenging the Prostate Cancer Myth26:40 - Erectile Dysfunction (ED) and Lifestyle Modification29:21 - Shockwave Therapy for ED: The Science and the Cash Business33:53 - Penile Tissue Atrophy and Venous Leak37:25 - The Role of Muscle Mass, Sarcopenia, and Sexual Function39:41 - The Single Best Marker for Male Health: Erectile Function42:02 - The Science of Cialis and Viagra (PDE5 Inhibitors)45:49 - The Viagra Story: From Heart Drug to ED Cure50:50 - Tadalafil (Cialis) as a Triple-Threat Drug (Cardiac, Urinary, Sexual)53:57 - The Role of Testosterone in Female Sexual Function55:20 - Hypogonadism: Diagnosis, Treatment, and Fertility RiskAbout the guests: Dr. Abraham Morgentaler is an Associate Clinical Professor of Urology at Harvard Medical School and founder of Men's Health Boston. He is an internationally recognized expert in men's health, particularly known for his pioneering work in testosterone therapy. Dr. Morgentaler is credited with reversing the long-held belief that testosterone therapy causes prostate cancer and is the author of several books on men's health. YouTubeLinkedInT4L EducationX/Twitter Dr. Tobias Kohler is the co-founder of the Erectile Restoration Outcomes Study (EROS) penile implant registry. In addition to his clinical and research activities, Dr. Kohler is active in education, providing mentorship to residents and fellows.Mayo Clinic ResearchGateLinkedIn

This week, Thomas sits down with Dr. Richard Schwartz, the founder of Internal Family Systems, for an in-depth discussion on the power of healing in groups, intergenerational and ancestral trauma healing, and the relationship between therapy and spirituality—all topics that are featured in their forthcoming book; Releasing Our Burdens: A Guide to Healing Individual, Ancestral, and Collective Trauma.Thomas and Dr. Schwartz dive deep into the phenomena of ancestral and collective "legacy burdens", which are traumas from our shared past that unconsciously drive our current behavior and societal conflicts. They share therapeutic and spiritual strategies for addressing these inherited wounds, and discuss the urgent need for what Thomas calls a “collective healing architecture” to mend social fragmentation and revitalize our democratic systems.They also share insights on the importance of our interconnection with the natural world and the need for safe spaces to access “Self Energy,” where the profound impacts of individual parts work can amplify collective healing.✨ Watch the video version of this episode on YouTube:

I sit down with Dr. David Rosmarin, an associate professor at Harvard Medical School and a pioneer bridging the worlds of spirituality and clinical psychology. We explore a powerful, yet often ignored, truth in mental health: that for many, emotional distress is a crisis of meaning and spirit. David shares the fascinating research from his work at McLean Hospital, and we tackle the tough questions—are we over-medicalizing normal human anxiety? Could connecting with our spiritual nature be a more effective path to healing? This is a crucial conversation about bringing the soul back into mental health care.00:00 Intro02:42 The Genesis of Spirituality05:12 How Do You Define Spirituality?10:32 The Chasm Between Patient Needs and Clinical Training12:08 Humanizing Care: From Medication to Meaning18:21 A Case Study: Crisis of Meaning20:37 The Four Steps to Face Anxiety28:41 Anxiety as an Existential Opportunity31:01 Spiritual Mentorship: Crisis and Healing Are One34:40 Are We Over-Pathologizing Normal Anxiety?37:17 The Benzodiazepine Crisis and Over-Medication41:21 How to Find Dr. Rosmarin's Work42:53 Conclusion Learn more about Dr. David Rosmarin:· dhrosmarin.com· spirit.mclean.harvard.eduIn The Space Between membership, you'll get access to LIVE quarterly Ask Amy Anything meetings (not offered anywhere else!), discounts on courses, special giveaways, and a place to connect with Amy and other like-minded people. You'll also get exclusive access to other behind-the-scenes goodness when you join! Click here to find out more --> https://shorturl.at/vVrwR - IG- https://tinyurl.com/ysvafdwc- FB - https://tinyurl.com/yc3z48v9- YT - https://tinyurl.com/ywdsc9vt- Web - https://tinyurl.com/ydj949kt Life, Death & the Space Between Dr. Amy RobbinsExploring life, death, consciousness and what it all means. Put your preconceived notions aside as we explore life, death, consciousness and what it all means on Life, Death & the Space Between.**Brought to you by:Dr. Amy Robbins | Host, Executive ProducerPodcastize.net | Audio & Video Production | Hosted on Acast. See acast.com/privacy for more information.

Why is dating so hard in midlife? Are we all sending mixed signals? Abe Morgentaler, MD & Marianne Brandon, PhD are the hosts of the Sex Doctors Podcast, where they deep dive into the science & psychology of sexual health & relationships.  Dr. Morgentaler is a Harvard trained MD who opened the first comprehensive men's health center in the US, is the leading authority in testosterone therapy, author of four books & currently the Blavatnik Faculty Fellow in Health & Longevity at Harvard Medical School.  Dr. Brandon is a clinical psychologist, author & futurist whose professional writing includes aging & sex, the challenges of monogamy & female low libido. In this episode, you'll hear both personal & professional perspectives about the dating pool & approaches including app culture, dick pics, gender equality, hormones, “the ick” & desire-killing control. If you like this episode, you'll also like episode 180: IS YOUR ATTACHMENT STYLE RUINING YOUR RELATIONSHIP? Guests:Theirshttps://www.facebook.com/thesexdoctorshttps://www.youtube.com/@thesexdoctorspodhttps://www.instagram.com/thesexdoctors/Hershttps://www.psychologytoday.com/us/blog/the-future-intimacyhttps://a.co/d/8smce3Chttps://www.linkedin.com/in/mariannebrandon-59224513/https://x.com/DrBrandonHishttps://www.linkedin.com/in/abraham-morgentaler-md-81628b6/https://x.com/DrMorgentalerhttps://t4leducation.com/https://a.co/d/hZHpFn0 Host:  https://www.meredithforreal.com/  https://www.instagram.com/meredithforreal/ meredith@meredithforreal.comhttps://www.youtube.com/meredithforreal  https://www.facebook.com/meredithforrealthecuriousintrovert  Sponsors: https://www.jordanharbinger.com/starterpacks/ https://www.historicpensacola.org/about-us/  00:00 — Midlife dating déjà vu01:00 — Where have the good ones gone?02:03 — Top complaints while dating03:10 — Picky or self-aware?04:02 — Tiny towns vs. big cities05:00 — Strangers, apps, and mistrust05:58 — Why men send dick pics07:00 — Filtering for “fast yes”08:05 — Who's actually relationship-minded?08:45 — Is app culture the problem?09:20 — Entertainment vs. reciprocity09:58 — Should serious daters ditch apps?10:40 — The slot-machine effect11:35 — Standards vs. pickiness12:15 — Are we avoiding compromise?13:20 — The myth of perfection14:05 — How good men spend time15:00 — Apps aren't on your side16:12 — Ancient brains, modern tools17:00 — Digital dating = amplified disappointment18:00 — Get out of the house19:00 — Pick the rRequest to join my private Facebook Group, MFR Curious Insiders https://www.facebook.com/share/g/1BAt3bpwJC/

Women, Wealth and Entrepreneurship Podcast Season 6, 2025Welcome to Women, Wealth & Entrepreneurship with Ariel Shaw, MBA! We want to increase your bottom line and create generational wealth that lasts way beyond you!  It's 2025 and we are in Season 6! Wow! How Exciting! This is the year of Focus and Continued Expansion. Our 2025 Media Participants Include Sylvia Dennis-Wray of Sylvia The Advocate; Mica Johnson of The Mica Johnson State Farm Agency; Shamica Davis of JTS Vacations LLC; LaQuita Brooks of The Motivational Maven.We welcome Dr. John C. Lipman, MD, FSIR. Founder & Medical Director of Atlanta Fibroid Center.Dr. John Lipman is a board-certified Interventional Radiologist and renowned authority in the non-surgical treatment of uterine fibroids. He is also a philanthropist, entrepreneur, and an award-winning public speaker. He received his Masters and Medical degrees from Georgetown University School of Medicine in 1985. He completed a residency in Diagnostic Radiology at Brigham & Women's Hospital, Harvard Medical School, and then did a fellowship in Vascular & Interventional Radiology at Yale-New Haven Hospital, Yale University School of Medicine.

Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) CEO Dr. Seth Lederman talked with Proactive's Stephen Gunnion about the company's collaboration with Massachusetts General Hospital, affiliated with Harvard Medical School, to advance the clinical development of TNX-1500. Lederman explained that the partnership supports an Investigator Initiated Phase 2 clinical trial focused on kidney transplant recipients. Study initiation is contingent on institutional review board (IRB) approval and FDA clearance of the investigator-initiated investigational new drug application (IND). The study will assess TNX-1500, an anti-CD40 ligand monoclonal antibody, alongside a low-dose regimen of tacrolimus. The goal is to reduce or potentially eliminate the need for conventional immunosuppressive therapy. “We believe that the relatively low dose of tacrolimus should not have the same side effects that are associated with the higher dose,” Lederman said. The company views TNX-1500 as a differentiated approach to transplant immunology, aiming for immunomodulation rather than traditional immunosuppression. If successful, the product could become a standalone therapy. “Ultimately, the TNX-1500 could be monotherapy,” he noted, with the current study designed for regulatory expediency. Lederman also highlighted longer-term potential, noting that TNX-1500 may have applications beyond transplantation, including autoimmune conditions such as lupus. Key features include once-monthly dosing and what the company believes is best-in-class potency, supported by completed pharmacokinetic and pharmacodynamic studies. #TonixPharmaceuticals #TNX1500 #KidneyTransplant #Immunotherapy #ClinicalTrials #TransplantMedicine #BiotechStocks #SethLederman #AutoimmuneResearch #PharmaNews

Today's conversation centers on a vital aspect  of our human experience. The enhancing richness and benefits of empathy. Meet Helen Riess, M.D., Founder and Chief Medical Officer of Empathetics.com. Dr. Riess is a clinical professor and research psychiatrist at Harvard Medical School who developed empathy education based on neuroscience research. Her groundbreaking  book, which is now in paperback, is entitled, “The Empathy Effect: 7 NEUROSCIENCE BASED KEYS  for Transforming the Way We LIVE, LOVE, WORK and CONNECT Across Differences.” In a fractured world, learning more about empathy could be just what we need!

Madelaine Weiss is a Harvard-trained Licensed Psychotherapist, Mindset Expert, and Board-Certified Executive, Career, and Life Coach who helps high-achieving professionals master their minds so they can sustain—and truly enjoy—success across every area of life.She is the co-author of The Handbook of Stressful Transitions Across the Lifespan and the author of the acclaimed new release Getting to G.R.E.A.T.: 5-Step Strategy for Work and Life.Continuing her mission to support leaders both at work and at home, Madelaine is launching What's Your Story?, a personal development workbook for children and the adults who care about them. Her expertise in this space is rooted in her past roles as Chair of the School Business Partnership and as a parenting educator for the Massachusetts court system.Madelaine also brings deep organizational experience to her work, having served as a group mental health practice administrative director, a corporate Chief Organizational Development Officer, and an associate director of an educational resource program at Harvard Medical School.As a sought-after corporate trainer, she has designed and delivered programs for organizations including Harvard Medical School, the American Bar Association, Legal Services Corporation, AARP, MedSense, Harvard Law School Association, the International Association of Business Communicators, the National Association of Realtors, the DC Academy of General Dentistry, the Wharton Innovation Summit, and the Bureau of National Affairs.Madelaine's insights have been featured on NBC, Bold TV, and FOX5, and she is a frequent guest expert on leading podcasts, including Major, Lindsey & Africa's Erasing the Stigma. Her writing has appeared in Thrive Global, Authority Magazine's Editors List, UpJourney, and My Perfect Financial Advisor.

How do you build an entire creative ecosystem? And what does it take to empower storytellers at scale? In this episode, Alex speaks with Emmy-nominated producer, writer, doctor and serial entrepreneur Mehret Mandefro, a visionary voice at the intersection of storytelling, healing and creative innovation. As co-founder and MD of Realness Institute, Mehret has spent years strengthening Africa's media landscape through training, mentorship and systemic infrastructure-building. She shares her remarkable journey from medicine to media, the origins of her “audiovisual medicine” artistic practice, and the powerful lessons learned from pioneering television in Ethiopia and developing talent across the continent. In a wide ranging conversation, Mehret also dives into: • Why creative infrastructure is the missing piece in global storytelling • How Realness Institute nurtures and de-risks new creative voices • The urgent need for producers to think like entrepreneurs • The role of technology and AI in elevating human stories • Why Africa is central to the future of film This is a conversation about creativity, systems change and the responsibility we all share in shaping the future of screen storytelling. About Mehret Mandefro Mehret Mandefro is an Emmy-nominated producer, writer, and entrepreneur working at the intersection of culture, commerce, and social impact. A former physician turned storyteller, she has dedicated her career to transforming how stories are made—and who gets to tell them. Born in Ethiopia and raised in America, Mehret is a transnational force in global media who has built several groundbreaking enterprises, including Truth Aid Media in New York, Kana TV in Addis Ababa, and the Realness Institute in Cape Town, a nonprofit dedicated to training and mentoring writers, producers, and directors across Africa and the diaspora. Her award-winning film and television work bridges documentary and fiction, revealing hidden truths across the human experience. Her credits include How It Feels to Be Free (American Masters), Sweetness in the Belly (Amazon), Difret (Netflix), The Cost of Inheritance (PBS), Little White Lie (PBS), and Ethiopia's first teen drama, Yegna. Recognized on Variety's list of the most impactful women in global entertainment, Mehret is a member of the Academy of Motion Picture Arts and Sciences and is currently building the African Film and Media Arts Collective with artist Julie Mehretu with the support of BMW. Mehret has a BA in Anthropology from Harvard University, an MD from Harvard Medical School, a MSc in Public Health from the London School of Hygiene and Tropical Medicine as a Fulbright Scholar, and a PhD in Cultural Anthropology from Temple University.

Start Your Transformation Now In this episode of the Transform Your Life podcast, I talk about the importance of living your own purpose in life rather than conforming to the expectations and ideals of others. I talk about how we can get stuck in careers, relationships, and situations that don't align with our true desires because we seek the approval of our parents, partners, and society. I ask you to explore whether you are truly living a purposeful, fulfilling life on your own terms or living your life for others. As I ask the last question, I think back to the 1991 movie, The Dead Poet's Society, and I think about the movie character named Neil. He wanted to pursue acting and loved it, but his stern father wanted him to go to Harvard Medical School. Neil hated the idea of medical school and found it soul-crushing, but he agreed. You'll have to watch the movie for the story's conclusion, but it's not uncommon for people to deny their own hopes, wishes, wants, and dreams and instead live their lives to please their parents. Often times cultural and familial pressures guide people down a path that doesn't fulfill them, and they live decades misaligned from their own purpose while trying to please others. So, it's important to ask whether you are living your own purpose or someone else's. Another purpose-robbing action that people often get into is seeking validation from others. This is a surefire way to live an unfulfilled life. For example, a friend of mine was constantly motivated by a desire for his father's approval, and that led him down an obsessive path of constantly trying to prove himself. This behavior disconnects you from your higher self and obscures your true purpose. You can't create an authentic life while dependent on external validation. I have found that the key to living your purpose is surrendering to your destiny and innate talents. This involves getting quiet, listening to your intuition, and taking aligned action. We must focus on the importance of being grateful and on contribution rather than achievement. Here are four key points you may want to keep in mind: Surrender to your innate talents and destiny.Listen to your intuition and take aligned action.Express gratitude and focus on contributing.Achievements will naturally follow purposeful contributions. You must examine whether you are living someone else's purpose or your own. If you are not thrilled by how you spend your days, you are likely conforming to others' expectations. I challenge you to get creative, listen within, and take steps each day to live your own purpose. Listen, apply, and enjoy! Transformational Takeaway When you are living your purpose, you are contributing your talents to activities that light you up, and you will experience true joy and fulfillment. Your key is being brave enough to live life on your own terms. Just do it. Mentioned Resources: EPISODE 280: History, Humanity, and Spiritual Ego. EPISODE 236: Living Life on Your Own Terms Let's Connect:Instagram | Facebook | YouTube | LinkedIn LIKED THE EPISODE?If you're the kind of person who likes to help others, then share this with your friends and family. If you have found value, they will too. Please leave a review on Apple Podcasts so we can reach more people. Listening on Spotify? Please leave a comment below. We would love to hear from you! With gratitude,Jim

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School, both in Boston, Massachusetts. In this inaugural episode, Dr Matulonis welcomed guest Taymaa May, MD, MSc, to discuss advances in gynecologic cancer surgery. Dr May is the director of Ovarian Cancer Surgery in the Division of Surgical Oncology at the Brigham and Women's Hospital in Boston, as well as an associate professor at Harvard Medical School. One of the biggest transformative changes in the field has been the introduction of minimally invasive surgery using laparoscopic and robotic platforms, Dr May emphasized. This allows for precise cancer staging surgery and faster patient recovery without compromising cancer outcomes, she noted. Complementing this has been the innovation of sentinel lymph node mapping, which uses technology, such as an infrared dye, to precisely identify and remove only the necessary lymph nodes. This offers equal staging precision and reduces patient morbidity with lower extremity lymphedema, a common adverse effect associated with older, extensive lymph node dissections, according to Dr May. The experts stressed the importance of consulting a gynecologic oncology surgeon, as national studies indicate that patients assessed and operated on by these specialists achieve the most optimal clinical outcomes. For advanced ovarian cancer, which often requires complex multivisceral resection to achieve optimal tumor removal, Dr May explained that surgical innovations are used to enhance recovery. For example, she noted that fluorescence angiography assesses blood flow in fresh bowel sutures intraoperatively, which helps ensure proper healing and minimizes complications. In cervical cancer, Dr May said that radical trachelectomy offers a safe, fertility-preserving option for young patients with suitable tumors. Furthermore, when determining treatment for patients with advanced ovarian cancer, she emphasized that personalization is key. Ultimately, Drs Matulonis and May reported that integrating surgical innovation into gynecologic cancer treatment protocols ensures optimal recovery, which is critical for patients to start subsequent treatments, like chemotherapy, on time.

For episode 273, we are continuing a new series on the Metta Hour, centered on kids, in honor of Sharon's first children's book, Kind Karl, coming out on December 9th!Co-authored by Jason Gruhl, this illustrated picture book is for 4-8 year-olds and is a new children's adaptation of Sharon's beloved book Lovingkindness. For this podcast series, Sharon speaks with educators, caregivers, and researchers about the ways meditation, mindfulness, and lovingkindness can impact children of all ages and the family systems that support them. For the second episode of the series, Sharon speaks with Dr. Christopher Willard.Chris is a clinical psychologist at Harvard Medical School and author of numerous publications for children and adults. An internationally sought-after speaker and mindfulness educator, his books include Growing Up Mindful, Raising Resilience, and Alphabreaths.In this conversation, Sharon and Chris speak about:The benefits of mindfulness in family systemsChris's personal journey with mindfulnessHow mindfulness can be accessible for kids Emotional growth and connection at any age Simple at-home practices Modeling calm compassion How kids can emotionally regulate The benefits of meditation in schools Challenges of technology in family lifeHow self-compassion prevents burnoutNurturing empathy, presence and resilience The goal of presence, not perfectionThe episode closes with Chris leading guided practice. You can learn more about Chris's work on his website, right here.To learn more about Sharon's forthcoming children's book, Kind Karl, and pre-order a copy with a special pre-order gift, you can visit Sharon's website, right here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to the O2X limited series Optimizing Parenthood - A Guide to Leading the Next Generation.Over this 5 episode limited series we will explore the science, strategies, and practical wisdom behind raising healthy, confident, and resilient young adults. Hosted by O2X Vice President of Government Brendan Stickles, this podcast brings together leading experts in sleep science, nutrition, fitness, psychology, and personal development to help parents navigate the complexities of modern parenting.Episode #2 features O2X Sleep & Fatigue Management Specialist Jaime Lee Tartar. Dr. Tartar is a Professor of Neuroscience at Nova Southeastern University (NSU). She serves as the neuroscience program director and research director for the NSU College of Psychology. She received her Bachelor of Science degree in Psychology from NSU and a Master of Arts degree in Psychology from Florida Atlantic University where she used EEG measure to detect subclinical neurological impairments. She earned her Ph.D. in the Behavioral Neuroscience program at the University of Florida where the focus of her research involved discovering long-term changes that occur in neurobiological pathways involved in stress responses and developing animal models of stress. During graduate school Dr. Tartar also served for 6 years in the U.S. Army Reserves. Dr. Tartar completed Postdoctoral Training at Harvard Medical School where she studied neurological consequences of sleep perturbations using in vitro electrophysiological recording techniques. She also received training in Sleep Medicine at Harvard Medical School. In her professional career Dr. Tartar was awarded an Honorary Doctorate from NSU based on her work and contributions to NSU and the scientific community. She was also the NSU Professor of the year at NSU in 2018 and received the NSU Excellence in Teaching Award in 2009. Dr. Tartar has received multiple funding grants through the Department of Education and has received research funding from the Department of Defense. She has published over 55 original research articles and has written several book chapters. Based on her expertise, she consults for multiple prestigious organizations and served on the scientific advisory board for the National Academy of Sports Medicine and regularly serves as a peer review panelist for NASA. Dr. Tartar is also a scientific advisor for Enchanted Wave, LLC where she oversees their research in using single channel EEG. She is the co-founder and President of The Society for NeuroSports — an academic organization for the field of Sports Neuroscience. Dr. Tartar's current research is focused on stress, sleep, and athletic performance in humans.Be sure to tune into the following episodes over the following weeks...Episode 1: Dr. Katy Turner on building confidence and resilience within young adults Episode 2: Dr. Jaime Tartar on optimizing sleep schedules for the whole family  Episode 3: Josh Lamont on creating fitness habits in our youthEpisode 4: Dr. Nick Barringer on developing sustainable and healthy eating habitsEpisode 5: Adam La Reau on introducing goal setting and habit building to young adultsBuilding Homes for Heroes:https://www.buildinghomesforheroes.org/Download the O2X Tactical Performance App:app.o2x.comLet us know what you think:Website - http://o2x.comIG - https://instagram.com/o2xhumanperformance?igshid=1kicimx55xt4f 

In the latest episode, The Fanbase Weekly co-hosts welcome special guests Matthew Noe (Lead Collection & Knowledge Management Librarian, Harvard Medical School) and Tim Smyth (Educator / Reading Specialist / Eisner-nominated author - Teaching with Comics & Graphic Novels) to discuss the latest geek news stories of the week, including AI's attacks on libraries, education, and knowledge, whether Ben Solo should return to the Star Wars films, and James Cameron's connection to Predator: Badlands.

Listen to JCO's Art of Oncology article, "The Man at the Bow" by Dr. Alexis Drutchas, who is a palliative care physician at Dana Farber Cancer Institute. The article is followed by an interview with Drutchas and host Dr. Mikkael Sekeres. Dr. Drutchas shares the deep connection she had with a patient, a former barge captain, who often sailed the same route that her family's shipping container did when they moved overseas many times while she was growing up. She reflects on the nature of loss and dignity, and how oncologists might hold patients' humanity with more tenderness and care, especially at the end of life. TRANSCRIPT Narrator: The Man at the Bow, by Alexis Drutchas, MD  It was the kind of day that almost seemed made up—a clear, cerulean sky with sunlight bouncing off the gold dome of the State House. The contrast between this view and the drab hospital walls as I walked into my patient's room was jarring. My patient, whom I will call Suresh, sat in a recliner by the window. His lymphoma had relapsed, and palliative care was consulted to help with symptom management. The first thing I remember is that despite the havoc cancer had wreaked—sunken temples and a hospital gown slipping off his chest—Suresh had a warm, peaceful quality about him. Our conversation began with a discussion about his pain. Suresh told me how his bones ached and how his fatigue left him feeling hollow—a fraction of his former self. The way this drastic change in his physicality affected his sense of identity was palpable. There was loss, even if it was unspoken. After establishing a plan to help with his symptoms, I pivoted and asked Suresh how he used to spend his days. His face immediately lit up. He had been a barge captain—a dangerous and thrilling profession that took him across international waters to transport goods. Suresh's eyes glistened as he described his joy at sea. I was completely enraptured. He shared stories about mornings when he stood alone on the bow, feeling the salted breeze as the barge moved through Atlantic waves. He spoke of calm nights on the deck, looking at the stars through stunning darkness. He traveled all over the globe and witnessed Earth's topography from a perspective most of us will never see. The freedom Suresh exuded was profound. He loved these voyages so much that one summer, despite the hazards, he brought his wife and son to experience the journey with him. Having spent many years of my childhood living in Japan and Hong Kong, my family's entire home—every bed, sheet, towel, and kitchen utensil—was packed up and crossed the Atlantic on cargo ships four times. Maybe Suresh had captained one, I thought. Every winter, we hosted US Navy sailors docked in Hong Kong for the holidays. I have such fond memories of everyone going around the table and sharing stories of their adventures—who saw or ate what and where. I loved those times: the wild abandon of travel, the freedom of being somewhere new, and the way identity can shift and expand as experiences grow. When Suresh shared stories of the ocean, I was back there too, holding the multitude of my identity alongside him. I asked Suresh to tell me more about his voyages: what was it like to be out in severe weather, to ride over enormous swells? Did he ever get seasick, and did his crew always get along? But Suresh did not want to swim into these perilous stories with me. Although he worked a difficult and physically taxing job, this is not what he wanted to focus on. Instead, he always came back to the beauty and vitality he felt at sea—what it was like to stare out at the vastness of the open ocean. He often closed his eyes and motioned with his hands as he spoke as if he was not confined to these hospital walls. Instead, he was swaying on the water feeling the lightness of physical freedom, and the way a body can move with such ease that it is barely perceptible, like water flowing over sand. The resonances of Suresh's stories contained both the power and challenges laden in this work. Although I sat at his bedside, healthy, my body too contained memories of freedom that in all likelihood will one day dissipate with age or illness. The question of how I will be seen, compared to how I hoped to be seen, lingered in my mind. Years ago, before going to medical school, I moved to Vail, Colorado. I worked four different jobs just to make ends meet, but making it work meant that on my days off, I was only a chairlift ride away from Vail's backcountry. I have a picture of this vigor in my mind—my snowboard carving into fresh powder, the utter silence of the wilderness at that altitude, and the way it felt to graze the powdery snow against my glove. My face was windburned, and my body was sore, but my heart had never felt so buoyant. While talking with Suresh, I could so vividly picture him as the robust man he once was, standing tall on the bow of his ship. I could feel the freedom and joy he described—it echoed in my own body. In that moment, the full weight of what Suresh had lost hit me as forcefully as a cresting wave—not just the physical decline, but the profound shift in his identity. What is more, we all live, myself included, so precariously at this threshold. In this work, it is impossible not to wonder: what will it be like when it is me? Will I be seen as someone who has lived a full life, who explored and adventured, or will my personhood be whittled down to my illness? How can I hold these questions and not be swallowed by them? "I know who you are now is not the person you've been," I said to Suresh. With that, he reached out for my hand and started to cry. We looked at each other with a new understanding. I saw Suresh—not just as a frail patient but as someone who lived a full life. As someone strong enough to cross the Atlantic for decades. In that moment, I was reminded of the Polish poet, Wislawa Szymborska's words, "As far as you've come, can't be undone." This, I believe, is what it means to honor the dignity of our patients, to reflect back the person they are despite or alongside their illness…all of their parts that can't be undone. Sometimes, this occurs because we see our own personhood reflected in theirs and theirs in ours. Sometimes, to protect ourselves, we shield ourselves from this echo. Other times, this resonance becomes the most beautiful and meaningful part of our work. It has been years now since I took care of Suresh. When the weather is nice, my wife and I like to take our young son to the harbor in South Boston to watch the planes take off and the barges leave the shore, loaded with colorful metal containers. We usually pack a picnic and sit in the trunk as enormous planes fly overhead and tugboats work to bring large ships out to the open water. Once, as a container ship was leaving the port, we waved so furiously at those working on board that they all started to wave back, and the captain honked the ships booming horn. Every single time we are there, I think of Suresh, and I picture him sailing out on thewaves—as free as he will ever be. Mikkael Sekeres: Welcome back to JCO's Cancer Stories: The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. What a treat we have today. We're joined by Dr. Alexis Drutchas, a Palliative Care Physician and the Director of the Core Communication Program at the Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School to discuss her article, "The Man at the Bow." Alexis, thank you so much for contributing to Journal of Clinical Oncology and for joining us to discuss your article. Dr. Alexis Drutchas: Thank you. I'm thrilled and excited to be here. Mikkael Sekeres: I wonder if we can start by asking you about yourself. Where are you from, and can you walk us a bit through your career? Dr. Alexis Drutchas: The easiest way to say it would be that I'm from the Detroit area. My dad worked in automotive car parts and so we moved around a lot when I was growing up. I was born in Michigan, then we moved to Japan, then back to Michigan, then to Hong Kong, then back to Michigan. Then I spent my undergrad years in Wisconsin and moved out to Colorado to teach snowboarding before medical school, and then ended up back in Michigan for that, and then on the east coast at Brown for my family medicine training, and then in Boston for work and training. So, I definitely have a more global experience in my background, but also very Midwestern at heart as well. In terms of my professional career trajectory, I trained in family medicine because I really loved taking care of the whole person. I love taking care of kids and adults, and I loved OB, and at the time I felt like it was impossible to choose which one I wanted to pursue the most, and so family medicine was a great fit. And at the core of that, there's just so much advocacy and social justice work, especially in the community health centers where many family medicine residents train. During that time, I got very interested in LGBTQ healthcare and founded the Rhode Island Trans Health Conference, which led me to work as a PCP at Fenway Health in Boston after that. And so I worked there for many years. And then through a course of being a hospitalist at BI during that work, I worked with many patients with serious illness, making decisions about discontinuing dialysis, about pursuing hospice care in the setting of ILD. I also had a significant amount of family illness and started to recognize this underlying interest I had always had in palliative care, but I think was a bit scared to pursue. But those really kind of tipped me over to say I really wanted to access a different level of communication skills and be able to really go into depth with patients in a way I just didn't feel like I had the language for. And so I applied to the Harvard Palliative Care Fellowship and luckily and with so much gratitude got in years ago, and so trained in palliative care and stayed at MGH after that. So my Dana-Farber position is newer for me and I'm very excited about it. Mikkael Sekeres: Sounds like you've had an amazing career already and you're just getting started on it. I grew up in tiny little Rhode Island and, you know, we would joke you have to pack an overnight bag if you travel more than 45 minutes. So, our boundaries were much tighter than yours. What was it like growing up where you're going from the Midwest to Asia, back to the Midwest, you wind up settling on the east coast? You must have an incredible worldly view on how people live and how they view their health. Dr. Alexis Drutchas: I think you just named much of the sides of it. I think I realize now, in looking back, that in many ways it was living two lives, because at the time it was rare from where we lived in the Detroit area in terms of the other kids around us to move overseas. And so it really did feel like that part of me and my family that during the summers we would have home leave tickets and my parents would often turn them in to just travel since we didn't really have a home base to come back to. And so it did give me an incredible global perspective and a sense of all the ways in which people develop community, access healthcare, and live. And then coming back to the Midwest, not to say that it's not cosmopolitan or diverse in its own way, but it was very different, especially in the 80s and 90s to come back to the Midwest. So it did feel like I carried these two lenses in the world, and it's been incredibly meaningful over time to meet other friends and adults and patients who have lived these other lives as well. I think for me those are some of my most connecting friendships and experiences with patients for people who have had a similar experience in living with sort of a duality in their everyday lives with that. Mikkael Sekeres: You know, you write about the main character of your essay, Suresh, who's a barge captain, and you mention in the essay that your family crossed the Atlantic on cargo ships four times when you were growing up. What was that experience like? How much of it do you remember? Dr. Alexis Drutchas: Our house, like our things, crossed the Atlantic four times on barge ships such as his. We didn't, I mean we crossed on airplanes. Mikkael Sekeres: Oh, okay, okay. Dr. Alexis Drutchas: We flew over many times, but every single thing we owned got packed up into containers on large trucks in our house and were brought over to ports to be sent over. So, I'm not sure how they do it now, but at the time that's sort of how we moved, and we would often go live in a hotel or a furnished apartment for the month's wait of all of our house to get there, which felt also like a surreal experience in that, you know, you're in a totally different country and then have these creature comforts of your bedroom back in Metro Detroit. And I remember thinking a lot about who was crossing over with all of that stuff and where was it going, and who else was moving, and that was pretty incredible. And when I met Suresh, just thinking about the fact that at some point our home could have been on his ship was a really fun connection in my mind to make, just given where he always traveled in his work. Mikkael Sekeres: It's really neat. I remember when we moved from the east coast also to the Midwest, I was in Cleveland for 18 years. The very first thing we did was mark which of the boxes had the kids' toys in it, because that of course was the first one we let them close it up and then we let them open it as soon as we arrived. Did your family do something like that as well so that you can, you know, immediately feel an attachment to your stuff when they arrived? Dr. Alexis Drutchas: Yeah, I remember what felt most important to our mom was our bedrooms. I don't remember the toys. I remember sort of our comforters and our pillowcases and things like that, yeah, being opened and it feeling really settling to think, "Okay, you know, we're in a completely different place and country away from most everything we know, but our bedroom is the same." That always felt like a really important point that she made to make home feel like home again in a new place. Mikkael Sekeres: Yeah, yeah. One of the sentences you wrote in your essay really caught my eye. You wrote about when you were younger and say, "I loved those times, the wild abandon of travel, the freedom of being somewhere new, the way identity can shift and expand as experiences grow." It's a lovely sentiment. Do you think those are emotions that we experience only as children, or can they continue through adulthood? And if they can, how do we make that happen, that sense of excitement and experience? Dr. Alexis Drutchas: I think that's such a good question and one I honestly think about a lot. I think that we can access those all the time. There's something about the newness of travel and moving, you know, I have a 3-year-old right now, and so I think many parents would connect to that sense that there is wonderment around being with someone experiencing something for the first time. Even watching my son, Oliver, see a plane take off for the first time felt joyous in a completely new way, that even makes me smile a lot now. But I think what is such a great connection here is when something is new, our eyes are so open to it. You know, we're constantly witnessing and observing and are excited about that. And I think the connection that I've realized is important for me in my work and also in just life in general to hold on to that wonderment is that idea of sort of witnessing or having a writer's eye, many would call it, in that you're keeping your eye open for the small beautiful things. Often with travel, you might be eating ramen. It might not be the first time you're eating it, but you're eating it for the first time in Tokyo, and it's the first time you've had this particular ingredient on it, and then you remember that. But there's something that we're attuned to in those moments, like the difference or the taste, that makes it special and we hold on to it. And I think about that a lot as a writer, but also in patient care and having my son with my wife, it's what are the special small moments to hold on to and allowing them to be new and beautiful, even if they're not as large as moving across the country or flying to Rome or whichever. I think there are ways that that excitement can still be alive if we attune ourselves to some of the more beautiful small moments around us. Mikkael Sekeres: And how do we do that as doctors? We're trained to go into a room and there's almost a formula for how we approach patients. But how do you open your mind in that way to that sense of wonderment and discovery with the person you're sitting across from, and it doesn't necessarily have to be medical? One of the true treats of what we do is we get to meet people from all backgrounds and all walks of life, and we have the opportunity to explore their lives as part of our interaction. Dr. Alexis Drutchas: Yeah, I think that is such a great question. And I would love to hear your thoughts on this too. I think for me in that sentence that you mentioned, sitting at that table with sort of people in the Navy from all over the world, I was that person to them in the room, too. There was some identity there that I brought to the table that was different than just being a kid in school or something like that. To answer your question, I wonder if so much of the challenge is actually allowing ourselves to bring ourselves into the room, because so much of the formula is, you know, we have these white coats on, we have learners, we want to do it right, we want to give excellent care. There's there's so many sort of guards I think that we put up to make sure that we're asking the right questions, we don't want to miss anything, we don't want to say the wrong thing, and all of that is true. And at the same time, I find that when I actually allow myself into the room, that is when it is the most special. And that doesn't mean that there's complete countertransference or it's so permeable that it's not in service of the patient. It just means that I think when we allow bits of our own selves to come in, it really does allow for new connections to form, and then we are able to learn about our patients more, too. With every patient, I think often we're called in for goals of care or symptom management, and of course I prioritize that, but when I can, I usually just try to ask a more open-ended question, like, "Tell me about life before you came to the hospital or before you were diagnosed. What do you love to do? What did you do for work?" Or if it's someone's family member who is ill, I'll ask the kids or family in the room, "Like, what kind of mom was she? You know, what special memory you had?" Just, I get really curious when there's time to really understand the person. And I know that that's not at all new language. Of course, we're always trying to understand the person, but I just often think understanding them is couched within their illness. And I'm often very curious about how we can just get to know them as people, and how humanizing ourselves to them helps humanize them to us, and that back and forth I think is like really lovely and wonderful and allows things to come up that were totally unexpected, and those are usually the special moments that you come home with and want to tell your family about or want to process and think about. What about you? How do you think about that question? Mikkael Sekeres: Well, it's interesting you ask. I like to do projects around the house. I hate to say this out loud because of course one day I'll do something terrible and everyone will remember this podcast, but I fancy myself an amateur electrician and plumber and carpenter and do these sorts of projects. So I go into interactions with patients wanting to learn about their lives and how they live their lives to see what I can pick up on as well, how I can take something out of that interaction and actually use it practically. My father-in-law has this phrase he always says to me when a worker comes to your house, he goes, he says to me, "Remember to steal with your eyes." Right? Watch what they do, learn how they fix something so you can fix it yourself and you don't have to call them next time. So, for me it's kind of fun to hear how people have lived their lives both within their professions, and when I practiced medicine in Cleveland, there were a lot of farmers and factory workers I saw. So I learned a lot about how things are made. But also about how they interact with their families, and I've learned a lot from people I've seen who were just terrific dads and terrific moms or siblings or spouses. And I've tried to take those nuggets away from those interactions. But I think you can only do it if you open yourself up and also allow yourself to see that person's humanity. And I wonder if I can quote you to you again from your essay. There's another part that I just loved, and it's about how you write about how a person's identity changes when they become a patient. You write, "And in that moment the full weight of what he had lost hit me as forcefully as a cresting wave. Not just the physical decline, but the profound shift in identity. What is more, we all live, me included, so precariously at this threshold. In this work, it's impossible not to wonder, what will it be like when it's me? Will I be seen as someone who's lived many lives, or whittled down only to someone who's sick?" Can you talk a little bit more about that? Have you been a patient whose identity has changed without asking you to reveal too much? Or what about your identity as a doctor? Is that something we have to undo a little bit when we walk in the room with the stethoscope or wearing a white coat? Dr. Alexis Drutchas: That was really powerful to hear you read that back to me. So, thank you. Yeah, I think my answer here can't be separated from the illness I faced with my family. And I think this unanimously filters into the way in which I see every patient because I really do think about the patient's dignity and the way medicine generally, not always, really does strip them of that and makes them the patient. Even the way we write about "the patient said this," "the patient said that," "the patient refused." So I generally very much try to have a one-liner like, "Suresh is a X-year-old man who's a barge captain from X, Y, and Z and is a loving father with a," you know, "period. He comes to the hospital with X, Y, and Z." So I always try to do that and humanize patients. I always try to write their name rather than just "patient." I can't separate that out from my experience with my family. My sister six years ago now went into sudden heart failure after having a spontaneous coronary artery dissection, and so immediately within minutes she was in the cath lab at 35 years old, coding three times and came out sort of with an Impella and intubated, and very much, you know, all of a sudden went from my sister who had just been traveling in Mexico to a patient in the CCU. And I remember desperately wanting her team to see who she was, like see the person that we loved, that was fighting for her life, see how much her life meant to us. And that's not to say that they weren't giving her great care, but there was something so important to me in wanting them to see how much we wanted her to live, you know, and who she was. It felt like there's some important core to me there. We brought pictures in, we talked about what she was living for. It felt really important. And I can't separate that out from the way in which I see patients now or I feel in my own way in a certain way what it is to lose yourself, to lose the ability to be a Captain of the ship, to lose the ability to do electric work around the house. So much of our identity is wrapped up in our professions and our craft. And I think for me that has really become forefront in the work of palliative care and in and in the teaching I do and in the writing I do is how to really bring them forefront and not feel like in doing that we're losing our ability to remain objective or solid in our own professional identities as clinicians and physicians. Mikkael Sekeres: Well, I think that's a beautiful place to end here. I can only imagine what an outstanding physician and caregiver you are also based on your writing and how you speak about it. You just genuinely come across as caring about your patients and your family and the people you have interactions with and getting to know them as people. It has been again such a treat to have Dr. Alexis Drutchas here. She is Director of the Core Communication Program at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School to discuss her article, "The Man at the Bow." Alexis, thank you so much for joining us. Dr. Alexis Drutchas: Thank you. This has been a real joy. Mikkael Sekeres: If you've enjoyed this episode, consider sharing it with a friend or colleague, or leave us a review. Your feedback and support helps us continue to save these important conversations. If you're looking for more episodes and context, follow our show on Apple, Spotify, or wherever you listen, and explore more from ASCO at ASCO.org/podcasts. Until next time, this has been Mikkael Sekeres for the ASCO podcast Cancer Stories: The Art of Oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Show notes: Like, share and subscribe so you never miss an episode and leave a rating or review. Guest Bio: Dr. Alexis Drutchas is a palliative care physician at Dana Farber Cancer Institute.

LAST CHANCE – Expires November 21! Dedifferentiated liposarcoma (DDLPS) poses significant challenges for diagnosis and management. In this expert‑led discussion, Dr. Richard F. Riedel (Duke University Medical Center) and Dr. Candace L. Haddox (Dana‑Farber Cancer Institute, Harvard Medical School) share practical insights on identifying MDM2/CDK4 amplification, exploring emerging treatments such as CDK4/6 inhibitors and immunotherapies, and improving outcomes through a multidisciplinary approach. Listen now and earn 0.5 CME credit: https://bit.ly/49GyP5T

What if AI could help solve medicine's biggest blind spots?Harvard Medical School researcher Dr. Charlotte Blease reveals why doctors can only keep up with 2% of new medical research and how artificial intelligence could transform healthcare for both patients and providers. Drawing from her new book Dr Bot: Why Doctors Can Fail and How AI Could Save Lives, she shares fascinating insights about the future of medical care.Part of the Future of Medicine series exploring innovations reshaping healthcare as we know it.You can find Charlotte at: Dr Bot Substack | Website | Episode TranscriptIf you LOVED this episode, don't miss a single conversation in our Future of Medicine series, airing every Monday through December. Follow Good Life Project wherever you listen to podcasts to catch them all.Check out our offerings & partners: Join My New Writing Project: Awake at the WheelVisit Our Sponsor Page For Great Resources & Discount CodesWatch Jonathan's new TEDxBoulder Talk on YouTube now: https://www.youtube.com/watch?v=2zUAM-euiVI Hosted on Acast. See acast.com/privacy for more information.

I am thrilled to have Dr. Olivera Bogunovic and Holly Hardman with me on the show today. Dr. Bogunovic is an assistant professor of psychiatry at Harvard Medical School and the medical director of the alcohol, drug, and addiction outpatient program at McLean Hospital. and Holly directed the documentary As Prescribed. In today's discussion, we dive into the ongoing benzodiazepine crisis in the United States, with over 92 million prescriptions written each year for medications like Ativan, Valium, Xanax, and Klonopin. We discuss the origin of those drugs in the 1970s as treatments for anxiety and how they lead to tremendous physical dependency. Holly shares her experience with the neurological effects she suffered after long-term use of Klonopin, and we examine challenges in psychiatric care, the need for informed consent, and the impact of social media. We also cover the role of lifestyle, the need for psychotherapy and psychosocial support, and the significance of hope. This conversation is truly invaluable! Given how frequently benzodiazepines get prescribed, everyone must understand their associated risks and considerations. IN THIS EPISODE YOU WILL LEARN: How prescribing practices have evolved over the last two decades The significant consequences older adults face when they suddenly stop using benzodiazepines  Holly shares how doctors misinformed her when she began taking Klonopin.  Holly describes the benzodiazepine-induced symptoms and cognitive issues she experienced Why people must get informed about the long-term effects of benzodiazepines when consenting to take them How benzodiazepines work in the body and impact the brain Why benzodiazepines are ineffective when used long-term for insomnia The challenges certain people face when accessing psychiatric care What is BIND, and what are its symptoms? The significance of diet and holistic approaches for managing mental health, and why community support is essential in the recovery process Why As Prescribed is an educational documentary for everyone Connect with Cynthia Thurlow   Follow on X ⁠Instagram⁠ ⁠LinkedIn⁠ Check out Cynthia's ⁠website⁠ Submit your questions to ⁠support@cynthiathurlow.com⁠ Connect with Dr. Olivera Bogunovic ⁠The McLean Hospital⁠  The documentary, As Prescribed, is available in the United States and Canada on Prime Video, Apple, Kanopy, Tubi, and Google.

It's simple to calm your nervous system in minutes using a meditation technique taught by Dr. Juna. In this episode of the MindBodySpace Podcast, Dr. Juna, a double board-certified radiologist and lifestyle medicine physician, guides you through a relaxation response method inspired by Dr. Herbert Benson's work at Harvard Medical School on meditation and blood pressure. You'll learn how to interrupt everyday thoughts, reduce stress, and activate your parasympathetic nervous system, resulting in a lower heart rate and relaxed muscle tension and a whole host of other benefits. For more resources, visit mindbodyspace.com00:00 Introduction to Relaxation Response00:33 Understanding Stress and Relaxation Response01:41 Guided Relaxation Exercise09:17 Concluding Thoughts and Resources

We kicked off the program with four news stories and different guests on the stories we think you need to know about!A new study ranks Massachusetts the best place to start a family! Guest: Kelli David - Client Director of Ivy Surrogacy, the company that conducted the study The Invincible Brain: The Clinically Proven Plan to Age-Proof Your Brain and Stay Sharp for Life. Guest: Dr. Majid Fotuhi (Pronounced: MA-JEED - FO-TWO-HEE) - PhD in Neuroscience from Johns Hopkins University in 1992 and his Medical Degree from Harvard Medical School in 1997. Currently serves as an adjunct professor at the Mind/Brain Institute at Johns Hopkins University, while also teaching at George Washington University & Harvard Medical School. Success Is a Numbers Game: Achieve Bigger Goals by Changing the Odds. Guest: Kyle Austin - award-winning strategy consultant, business writer and author - writer for Harvard Business Review, The Boston Globe, CNBC, Psychology Today, Forbes, and Business Insider The Rembrandt Heist: The Story of a Criminal Genius, a Stolen Masterpiece, and an Enigmatic Friendship Guest: Anthony Amore – author & director of security and chief investigator at the Isabella Stewart Gardner Museum in Boston.See omnystudio.com/listener for privacy information.

Ochelli Effect 11-5-2025 SNAFU NEWSThis week we released some old shows and if that gets a few more downloads than new shows, we might keep doing so until Chuck Returns from Texas around the 25th. We had to do at least one SNAFU NEWS before Friday when we plan to have LIVE events, -8pm , The Regular Call-in show 8-10pm, Ae of Transitions 10-11pm & Uncle The Podcast 11pm-Midnight. LL Times Eastern)SELECTION NIGHT 2025 + SHUTDOWN RUNDOWN = AMERICA LAST ?Bomb threats in New Jersey and Trump warnings for California mark Election Dayhttps://apnews.com/article/election-2025-voting-threats-monitors-ballots-225eba3f30c8697924fc166ed9996736?Democrats sweep key races in 2025 elections in early referendum on Trumphttps://www.cbsnews.com/live-updates/election-day-2025-voting-results/ Americans will still get partial SNAP benefits despite Trump post, White House saysThe clarification comes after the president threatened on Truth Social to withhold federal food aid funding until Democrats agree to reopen the government. https://www.politico.com/news/2025/11/04/trump-snap-funding-shutdown-food-aid-00635141Trump administration warns shutdown could force US airspace closureshttps://www.theguardian.com/us-news/2025/nov/04/government-shutdown-airspace-flight-delays---SNAFU EFFECTTwo men accused of plotting terror attacks at LGBTQ+ bars in the Detroit areahttps://apnews.com/article/michigan-arrests-terror-plot-f47736ddf21df6614f75fb932d6aeac4?China denies nuclear testing, calls on US to maintain moratoriumUS president claims China, Russia have carried out secret nuclear weapon tests as he seeks to justify return to testing.https://www.aljazeera.com/news/2025/11/3/china-denies-nuclear-testing-calls-on-us-to-maintain-moratoriumCBS News heavily edits Trump 60 Minutes interview, cutting boast network ‘paid me a lotta money'Trump said Paramount's sale to David and Larry Ellison was ‘greatest thing that's happened in a long time' for free presshttps://www.theguardian.com/us-news/2025/nov/03/trump-cbs-60-minutes-interview-editedAUDIO word from Mike SwansonMICHAEL SWANSONBE IN THE KNOW: Sign-up for The email listhttps://wallstreetwindow.comFACEBOOK:https://www.facebook.com/tradermike BY MICHAEL SWANSON:The War State: The Cold War Origins Of The Military-Industrial Complex And The Power Elite, 1945-1963https://www.amazon.com/gp/product/B00EWLGXHW/ref=dbs_a_def_rwt_bibl_vppi_i0Scenario Hypothetical = You discover your neighbor is either Fuentes or Carlson. A: How fast do you arrange to move your family a safe distance away? B: How long before Israel needs a preemptive strike because Tucker and Nick are less than 2 years from possessing Nukes? C: Do you finally commit to siding with the Warts and all element in modern Trumpism formerly known as The Republican Party, or side against it with something that makes sense which also automatically means no Woke, and Post-Woke American Democrats?Tucker Carlson's interview with far-right antisemite Nick Fuentes divides conservativeshttps://www.theguardian.com/us-news/2025/oct/31/conservative-reaction-tucker-carlson-nick-fuentes-interviewTucker Carlson under fire for Nick Fuentes interviewhttps://www.youtube.com/shorts/9_Z87k2rN1wCheck The whole interview and let Chuck know what clip he missed that is chocking PLEASE. Also he will come up with a prize for somebody who can begin to make a convincing case, This isn't simply a well planned PR uplift for both of them to raise money for The Groyper Army and solidify Tucker as the Alt Media 3.1 hero they've been selling him as since he left Alphabet Cereal land corporate media and occupy the space Charlie Kirks successors have already failed to keep a hold on?Listen for Yourself if you like...Tucker Carlson Interviews Nick Fuenteshttps://www.youtube.com/watch?v=efBB0D4tf1YCarlson is a Content generator who has been inserted into the LEFT/RIGHT paradigm in every angle possible. He has been platformed and highly paid to infect nearly every ideological corner in American political discourse. Currently on his own branded platform today he has a long history of being employed by, everyone.Groyper Army = group of white Christian nationalists are followers, fans, or associates of American far-right figure and content creator  Nick Fuentes. The name is partially inspired by a variant of Pepe the Frog but there is a great deal of nuance absent in this definition.ALSO ALSOSeymour HershHOW DICK CHENEY MADE ME A BETTER REPORTERhttps://seymourhersh.substack.com/p/how-dick-cheney-made-me-a-better?utm_source=postKentucky plane crash: death toll rises to 12 as officials investigate how engine detachedhttps://www.theguardian.com/us-news/2025/nov/05/ups-plane-crash-louisville-investigationDid Chuck mention the post-assassination Jackie Kenney Halloween costume controversy? ---FROM THE APAP Afternoon Wire HEADLINESFrom Tuesday 11-4-2025 Sir David Beckham: Soccer star is knighted by King Charles III for services to sport and charityMedieval tower collapse: Worker dies after 11 hours trapped within partially collapsed medieval tower in RomeObit: Mona Ziade, who helped shape the AP's Middle East coverage in the 1980s and ‘90s, dies at age 65Harvard explosion: 2 Massachusetts men have been arrested in the weekend explosion at Harvard Medical School, FBI saysGrand slam: Denny's to be acquired and taken private in a deal valued at $620 millionClimate: Pets contribute to greenhouse gases like us. Here's how to reduce their carbon pawprintWATCH: Christmas harvest begins in Germany, where some say decorating trees began---FROM THE RUNDOWNBomb threats in New Jersey and Trump warnings for California mark Election Dayhttps://apnews.com/article/election-2025-voting-threats-monitors-ballots-225eba3f30c8697924fc166ed9996736?It's never been easier to be a conspiracy theoristhttps://www.technologyreview.com/2025/10/30/1126457/its-never-been-easier-to-be-a-conspiracy-theorist/Venezuela Strikes Fall Short of Triggering Legal Limits, White House Sayshttps://www.military.com/daily-news/2025/11/03/venezuela-strikes-fall-short-of-triggering-legal-limits-white-house-says.html Idiot Media Ignore 40 Years Of History To Pretend Trump Attacks On Cartels Are Unprecedentedhttps://thefederalist.com/2025/11/04/idiot-media-ignore-40-years-of-history-to-pretend-trump-attacks-on-cartels-are-unprecedented/Dick Cheney Dies at 84—Unfortunately Not at The Haguehttps://newrepublic.com/post/202647/dick-cheney-dies-iraq-war-torture-no-regretsCheney, architect of endless war, helped kill our faith in leadershttps://responsiblestatecraft.org/dick-cheney-dies/ Israel rocked by scandal as top military lawyer resigns, goes missing, is found and thrown into jailhttps://apnews.com/article/israel-military-scandal-prisoners-abuse-7becb2de4079b76b656910cc3c640d0d Israeli soldiers defend torturing Palestinian prisoner, saying they deserve thankshttps://www.middleeastmonitor.com/20251104-israeli-soldiers-defend-torturing-palestinian-prisoner-saying-they-deserve-thanks/Here's the Only 40 Seconds of Fox News Covering Trump Not Knowing Who He Pardonedhttps://www.mediaite.com/media/tv/heres-the-only-40-seconds-of-fox-news-covering-trump-not-knowing-who-he-pardoned/Support Newsvandal / PayPalhttps://newsvandal.us8.list-manage.com/track/click?u=15a14ef5fbdec40eb0032a960&id=a1b4a4f870&e=0f82208480---BE THE EFFECTSUPPORT Ochelli and The NetworkMrs.OLUNA ROSA CANDLEShttp://www.paypal.me/Kimberlysonn1---NOVEMBER IN DALLAS LANCER CONFERENCENOVEMBER 21-23 2025DISCOUNT FOR YOU10 % OFF code = Ochelli10https://assassinationconference.com/The Fairmont Dallas hotel 1717 N Akard Street, Dallas, Texas 75201. situated with easy access to Dealey PlazaChuck will be the Emcee & A LIVE Myths Panel is PlannedBE THE EFFECTListen/Chat on the Sitehttps://ochelli.com/listen-live/TuneInhttp://tun.in/sfxkxAPPLEhttps://music.apple.com/us/station/ochelli-com/ra.1461174708Ochelli Link Treehttps://linktr.ee/chuckochelliAnything is a blessing if you have the meansWithout YOUR support we go silent.---NOVEMBER IN DALLAS LANCER CONFERENCEDISCOUNT FOR YOU10 % OFF code = Ochelli10https://assassinationconference.com/Coming SOON Room Discount Details The Fairmont Dallas hotel 1717 N Akard Street, Dallas, Texas 75201. easy access to Dealey Plaza

Dr. Luiza Raab-Pontecorvo is a 4th-degree black belt in Tae Kwon Do and Jiujitsu, a Carnegie Hall and Broadway musician, and an international speaker, wellness coach, and entrepreneur. Featured in the award-winning documentary Breakthrough, she combines her diverse expertise in performance, neuroscience, and human potential to help others reach their peak.Holding a PhD in Musical Arts, certification in Lifestyle & Wellness Coaching from Harvard Medical School, and advanced training in Neuroscience, NLP, and Tony Robbins Leadership Academy, Dr. Luiza bridges art, science, and discipline in all she does.She is the founder of Atomic Tae Kwon Do, integrating psychology and leadership into martial arts, and Empowered Coaching, focused on women's safety, peak performance, and wellness strategies. Her music career has taken her across the globe with performances in Germany, Austria, England, Korea, China, Norway, Sweden, Switzerland, France, the Czech Republic, and Poland.

A Cleveland TV news reporter who once told other people’s stories becomes the subject of her own. Two Massachusetts men are charged after allegedly setting off a commercial firework inside Harvard Medical School. Drew Nelson reports.See omnystudio.com/listener for privacy information.

Sleep deprivation is a form of torture, yet we are depriving ourselves of quality sleep more than ever. Six out of 10 adults in the U.S. aren't getting enough sleep, which leads to negative mood, low energy, poor cognitive function, and can even take years off your life. In this episode, host Samantha Laine Perfas talks with sleep scientist Rebecca Robbins, psychiatrist Tony Cunningham, and epidemiologist Matthew Weaver about why we should – and how to – get better sleep.

We start with the final hours of voting in key races across the country. Anxiety around travel spikes as the government barrels towards its longest shutdown. Authorities made arrests in connection with a blast at Harvard Medical School. There's a major recall impacting some Jeep SUVs worldwide. Plus, a new hurdle in the fight against climate change.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

This popular episode replay features Dr. David H. Rosmarin, an associate professor at Harvard Medical School, a program director at McLean Hospital, and founder of Center for Anxiety, which services over 1,000 patients/year in multiple states. He is an international expert on spirituality and mental health, whose work has been featured in Scientific American, the Boston Globe, the Wall Street Journal, and the New York Times. Through his work as a clinical psychologist, scientist, educator and author, Dr. Rosmarin has helped thousands of patients and organizations to live happier and more productive lives. His most recent book is Thriving with Anxiety: 9 Tools to Make Your Anxiety Work for You Key Topics: - The current anxiety epidemic and what is causing it - Anxiety as a stepping stone to connection - How fear is a natural alert - How anxiety makes us connect to others better - The difference between stress and anxiety - How anxiety enhances spirituality - Hope for the person who's drowning in anxiety - The least known contributor to anxiety Learn more about Dr. Rosmarin and get his book at drrosmarin.com and centerforanxiety.org. Join Erin's monthly mailing list to get health tips and fresh meal plans and recipes every month: https://mailchi.mp/adde1b3a4af3/monthlysparksignup Order Erin's new book, Live Beyond Your Label, at erinbkerry.com/upcomingbook/ Buy Erin's recipe book, co-written by pediatrician Dr. Alina Olteanu here: https://a.co/d/ateoVxx

AP correspondent Haya Panjwani reports on an explosion at Harvard Medical School.

Milk has long been sold as the key to strong bones, but research challenges that claim: many people don't tolerate dairy, calcium needs are lower than advertised, and higher milk intake doesn't necessarily prevent fractures. Politics and industry marketing helped set “three glasses a day,” even though healthy bones depend more on overall diet and lifestyle—things like vitamin D, movement, and avoiding soda, excess sugar, and stress that drive calcium loss. Dairy may be helpful for some diets, but it can also trigger bloating, acne, congestion, or digestive issues. The good news is that strong bones and good nutrition are still very doable without cow's milk—think leafy greens, sardines, almonds, chia, and sunshine for vitamin D. In this episode, I discuss, along with Dr. David Ludwig and Dr. Elizabeth Boham why bone health depends more on diet, lifestyle, and nutrient balance than on dairy. David S. Ludwig, MD, PhD, is an endocrinologist and researcher at Boston Children's Hospital, Professor of Pediatrics at Harvard Medical School, and Professor of Nutrition at the Harvard T.H. Chan School of Public Health. He co-directs the New Balance Foundation Obesity Prevention Center and founded the Optimal Weight for Life (OWL) program, one of the nation's largest clinics for children with obesity. For over 25 years, Dr. Ludwig has studied how diet composition affects metabolism, body weight, and chronic disease risk, focusing on low glycemic index, low-carbohydrate, and ketogenic diets. Called an “obesity warrior” by Time Magazine, he has championed policy changes to improve the food environment. A Principal Investigator on numerous NIH and philanthropic grants, Dr. Ludwig has published over 200 scientific articles and three books for the public, including the #1 New York Times bestseller Always, Hungry? Dr. Elizabeth Boham is Board Certified in Family Medicine from Albany Medical School, and she is an Institute for Functional Medicine Certified Practitioner and the Medical Director of The UltraWellness Center. Dr. Boham lectures on a variety of topics, including Women's Health and Breast Cancer Prevention, insulin resistance, heart health, weight control and allergies. She is on the faculty for the Institute for Functional Medicine. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN to save 15%. Full-length episodes can be found here:Why Most Everything We Were Told About Dairy Is Wrong Is It Okay To Eat Cheese And What Types Of Dairy Should You Avoid? Is Lactose Intolerance Causing Your Gut Issues?

National security expert Juliette Kayyem on the investigation into an explosion at a Harvard Medical School building over the weekend, and President Trump's continued attacks on Venezuelan boats, even as the UN cites human rights violations. Plus, why he's threatening U.S. military action in Nigeria.Carol Rose of the ACLU of Massachusetts discusses the ACLU-led class action suit on behalf of detained immigrants who have been denied bond hearings. Plus, whether the U.S. supreme court will hand Trump yet another major victory on tariffs. Michael Curry of the Mass League of Community Health Centers on the government shutdown, healthcare costs and remembering his friend, former Newton mayor Setti Warren.David Shapiro of the YMCA of Greater Boston on how the Y is meeting Boston's food needs during the shutdown.  Alexander Smalls is an award-winning opera singer turned James Beard Award-winning cookbook author and chef. He joins us ahead of an event at Suffolk University.

John Edward Mack (October 4, 1929 – September 27, 2004) was an American psychiatrist, writer, and professor of psychiatry. He served as the head of the department of psychiatry at Harvard Medical School from 1977 to 2004. In 1977, Mack won the Pulitzer Prize for his book A Prince of Our Disorder on T. E. Lawrence.Mack's clinical expertise was in child psychology, adolescent psychology, and the psychology of religion. He was also known as a leading researcher on the psychology of teenage suicide and drug addiction, and he later became a researcher in the psychology of alien abduction experiences.Help us buy a camera:https://ko-fi.com/monsterfuzzSupport the pod:www.patreon.com/monsterfuzz Check out our merch:https://monster-fuzz.creator-spring.com Become a supporter of this podcast: https://www.spreaker.com/podcast/monster-fuzz--4349429/support.

Still no end in sight for ending the government shutdown. Dodgers win 2025 MLB World Series. Thwarted terrorist attack: Michigan attorneys say there was no attack planned despite FBI claims. Explosion at Harvard Medical School appears to have been intentional, authorities say. Mid-term elections tomorrow. China will make ‘substantial' purchases of U.S. soybeans and should avoid 100% tariff. Trump says there 'could be' US troops on the ground in Nigeria, or air strikes. Affordability and child care. The dangers of AI ChatBots. The problems with supermarket self-checkouts. Traffic worsening as return-to-the office rules take effect. 

In this episode of the Dietitian Boss podcast, Libby Rothchild, founder of Dietitian Boss, engages in a conversation with Stacy Dunn, MS, RDN, founder of Nutrition Jobs and Dietitian Salaries. Stacy shares her expertise on how dietitians can leverage LinkedIn to grow their business, build their brand, and network more effectively. The discussion covers everything from optimizing your LinkedIn profile, overcoming myths about the platform, strategic content posting, and creating an impactful personal brand. Stacy also provides actionable tips for dietitians who only have 10 minutes a day to invest in LinkedIn. 00:00 Introduction to Dietitian Boss Podcast 00:37 Meet Stacy Dunn: Career Expert for Dietitians 02:06 LinkedIn Misconceptions and Opportunities 03:41 Success Stories and Effective LinkedIn Strategies 05:20 Optimizing Your LinkedIn Profile 06:47 Content Creation and Engagement on LinkedIn 10:27 Personal Branding and Authority Building 23:58 Maximizing LinkedIn in 10 Minutes a Day 27:53 Final Thoughts and Membership Invitation Bio: Stacey Dunn-Emke, MS, RDN is a Registered Dietitian and the Founding Owner of NutritionJobs, a career portal for dietitians and nutrition professionals and DietitianSalaries.com, an anonymous salary survey tool. She is the author of The Dietetic Resume Guide and specializes in boosting professional opportunities for dietitians, students, and interns, with jobs, coaching and courses on Creating a Modern Winning Dietetic Resume, An Optimized LinkedIn Profile, and Job Interview Prep. Stacey regularly hosts LinkedIn Live Events, spotlighting dietitian careers and modern employment opportunities, aiming to build confidence and knowledge. Stacey brings her vast work experience to the dietetic career coaching table, where she has worked as a Clinical Dietitian, Nutrition Writer, Outpatient Dietitian, Clinical Nutrition Manager, and Research Dietitian with Dr. Dean Ornish. She has appeared on the Oprah Winfrey Show and MSNBC TV. She is a frequent speaker, including for The Academy of Nutrition and Dietetics, The California Academy of Nutrition and Dietetics, and Harvard Medical School. She has served on the Board of the Bay Area Dietetic Association, including President-Elect, was awarded Outstanding Dietitian, Outstanding Dietitian of the Year, and Recognized Young Dietitian. She lives with her family in San Francisco. Connect with Libby: Instagram: @libbyrothschild | @dietitianboss YouTube: Dietitian Boss Connect with (Guest Name) Instagram: @nutritionjobs

Federal investigators are searching for whoever dumped hundreds of cremated human bodies in the Nevada desert. An explosion inside a Harvard Medical School research building is under investigation after authorities said the blast appeared to be intentional. Drew Nelson reports.See omnystudio.com/listener for privacy information.

Reclaim your cognitive sovereignty by harnessing precision frequency medicine to counteract digital overload. This breakthrough Restorative Audio combines ancestral sound wisdom with cutting-edge neuroscience research from Harvard Medical School and Massachusetts General Hospital, utilizing three therapeutic frequency protocols—alpha wave entrainment (8-12 Hz), the Perfect Fifth interval for autonomic balance, and precision binaural beats—to measurably restore your overwhelmed neural networks.The ScienceResearch demonstrates that chronic digital saturation suppresses the parasympathetic nervous system while hyperactivating the amygdala, creating perpetual cognitive overload. Brain wave entrainment through therapeutic frequencies reverses this damage: studies show 23% cortisol reduction, improved heart rate variability, and enhanced cognitive performance within 20-minute sessions. The Perfect Fifth interval (C 256 Hz with G 384 Hz) stimulates nitric oxide production and pituitary endogenous opiates, while alpha-theta frequencies synchronize neural oscillations with Earth's Schumann Resonance, promoting measurable systemic coherence.Real-World Benefits- Reduces cortisol levels and restores autonomic nervous system balance- Enhances cognitive flexibility and creative problem-solving capacity- Improves focus without tension through optimal alpha-theta threshold- Decreases perceived stress and mental fatigue- Upregulates cellular repair genes and promotes neuroplasticity- Measurable improvements in heart rate variability and inflammatory markersUsage GuideFrequency:Daily 15-20 minute sessions for optimal neurological recalibration  Equipment:Quality headphones for precise binaural beat delivery  Environment:Low-EMF settings enhance therapeutic response  Best Results:4-6 weeks consistent practice for epigenetic gene expression changes  Hydration:Increase water intake to enhance cellular conductivity and frequency responseSubscribe for extended 30, 60, and 90-minute sessions and full Restorative Audio library access.Send us a textSupport the show

Reclaim your cognitive sovereignty by harnessing precision frequency medicine to counteract digital overload. This breakthrough Restorative Audio combines ancestral sound wisdom with cutting-edge neuroscience research from Harvard Medical School and Massachusetts General Hospital, utilizing three therapeutic frequency protocols—alpha wave entrainment (8-12 Hz), the Perfect Fifth interval for autonomic balance, and precision binaural beats—to measurably restore your overwhelmed neural networks.The ScienceResearch demonstrates that chronic digital saturation suppresses the parasympathetic nervous system while hyperactivating the amygdala, creating perpetual cognitive overload. Brain wave entrainment through therapeutic frequencies reverses this damage: studies show 23% cortisol reduction, improved heart rate variability, and enhanced cognitive performance within 20-minute sessions. The Perfect Fifth interval (C 256 Hz with G 384 Hz) stimulates nitric oxide production and pituitary endogenous opiates, while alpha-theta frequencies synchronize neural oscillations with Earth's Schumann Resonance, promoting measurable systemic coherence.Real-World Benefits- Reduces cortisol levels and restores autonomic nervous system balance- Enhances cognitive flexibility and creative problem-solving capacity- Improves focus without tension through optimal alpha-theta threshold- Decreases perceived stress and mental fatigue- Upregulates cellular repair genes and promotes neuroplasticity- Measurable improvements in heart rate variability and inflammatory markersUsage GuideFrequency:Daily 15-20 minute sessions for optimal neurological recalibration  Equipment:Quality headphones for precise binaural beat delivery  Environment:Low-EMF settings enhance therapeutic response  Best Results:4-6 weeks consistent practice for epigenetic gene expression changes  Hydration:Increase water intake to enhance cellular conductivity and frequency responseSubscribe for extended 30, 60, and 90-minute sessions and full Restorative Audio library access.Send us a textSupport the show

An explosion at Harvard Medical School early Saturday morning. Police release photos of two suspects after two individuals were seen fleeing the scene.The Trump administration says payments of food aid benefits might continue by Wednesday. NTD's Arian Pasdar has more on the Treasury's effort to continue the food stamps program and to reopen the government.Despite it being an off year, there's a lot on the line in Tuesday's election. An investigator and a city council candidate joins us to unpack the crucial races in New York City and Virginia.Are green vegetables and natural grains really as healthy as we think? A physician explains the perks of a meat-based diet in our preview of Vital Signs.And, celebrations in Egypt's capital mark opening day for the Grand Egyptian Museum. Details on the billion-dollar project, and why the Egyptian President says it marks 'new chapter' for the country.

En este episodio de Familias Horribles, conversamos con el Dr. Cristian Zanartu, médico internista y especialista en cuidados paliativos formado en Mount Sinai (afiliado a Columbia University, NY), con entrenamiento en Harvard Medical School.El Dr. Zanartu comparte su recorrido desde la medicina tradicional (donde el paciente se convierte en un “caso clínico”) hasta encontrar una práctica más humana, donde la persona vuelve a ser el centro. Hoy trabaja integrando ciencia, psicoterapia y medicina asistida con ketamina para sanar heridas invisibles: las del alma, el trauma y la pérdida.Con sensibilidad y profundidad, explica cómo el trauma se queda alojado en el cuerpo, cómo las partes internas que alguna vez nos protegieron pueden volverse contra nosotros, y cómo la ketamina, en un contexto terapéutico, puede ayudar a liberar esas memorias, acceder a lo reprimido y permitir que la compasión entre en lugares donde antes solo había dolor.Exploramos temas como:⭐️ El costo emocional de un sistema médico que trata órganos y no personas.⭐️ Qué ocurre cuando la mente se desconecta del cuerpo por trauma.⭐️ Cómo la ketamina terapéutica puede facilitar procesos de reparación emocional.⭐️ La diferencia entre curar y sanar.⭐️ Qué significa acompañar sin volver a traumatizar.⭐️ El diálogo entre ciencia, alma y compasión.⭐️ Por qué sanar requiere tiempo, presencia y amor.Un episodio profundamente humano y revelador sobre lo que ocurre cuando la medicina deja de ser un protocolo y vuelve a ser un encuentro entre dos seres humanos.

In this episode, we explore how mindfulness and yoga can help you decompress stress naturally, both mentally and physically. Modern science continues to confirm what ancient traditions have known for centuries.  That the mind and body are deeply connected, and that mindful presence is one of the antidotes to stress.  Research from institutions like Harvard Medical School and the National Institutes of Health (NIH) shows that mindfulness meditation and yoga lower levels of cortisol---the body's primary stress hormone. They also activate the parasympathetic nervous system, the body's natural “rest and digest” mode, which slows heart rate, improves focus, and promotes emotional regulation. You'll discover simple yet powerful practices that quiet mental distractions, release stored tension, and help you cultivate balance. Learn practical ways to help you navigate life's challenges. Get ready to decompress, improve focus, and feel grounded—whether you're at home, at work, or on the go.

Send us a textC4 Leaders – the ONLY nonprofit to utilize the pizza making process to create space for our companions to be seen, heard, and loved.   We work with businesses, sports teams, hospitals, churches…anyone looking to RISE TOGETHER.  We also write children's books and use the most amazing handmade, hand-tossed, sourdough pizza to bring out the best in each other.   Please check out PIZZADAYS.ORG to support our important work. Season 5 Episode #23 Dr. Kate Lund is coming from Edmonds, Washington (inform, inspire, & transform)You can find via her website katelundspeaks.comAbout our guest: Growing up with Hydrocephalus took the ordinary out of her childhood. Numerous surgeries, countless doctor visits and relentless recovery periods had become the norm for Kate.  But through it all, she found one thing that kept her thriving – the power of resilience in extraordinary circumstances. Building her life around finding incredible possibility on the other side of challenge kept her driven and ultimately helped Kate find her true calling.Today, Kate is a licensed clinical psychologist of 15 years, peak performance coach, best-selling author and TEDx speaker. Her specialized training in medical psychology includes world-renowned Shriners Hospital for Children, Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center, all of which are affiliated with Harvard Medical School. Kate uses a strengths-based approached to help her clients improve their confidence in school, sports and life while helping them to become more resilient and reach their full potential at all levels.Thanks for sharing your many gifts, for putting your courage, thoughts, experience, and insight on paper (three times) and for guiding all people to see life's adversities as opportunities for growth and understanding.   Welcome to the show! TOTD – “Your actions are your only true belongings.”  Thich Nhat HanhBuild a habit - to create intention - to live your purpose! In this episode:What was life like growing up?What are your life's essential ingredients?What is ResilienceThe power of managing our emotions – RULER…Self-Awareness, Social Awareness, Self-Management, Practical tools to use to help maintain homeostasis…Mantra…FriendshipSocial Demands of being humanBooks you recommendLegacy 

In this Huberman Lab Essentials episode, my guest is Dr. David Sinclair, PhD, a professor of genetics at Harvard Medical School and a leading expert on the biology of aging. We discuss the cellular and molecular mechanisms of aging—and how specific behaviors, such as fasting, regular exercise and NAD⁺-boosting compounds like NMN, can activate the body's natural longevity pathways. This discussion highlights how lifestyle choices profoundly influence the aging process and may even slow or reverse key aspects of biological aging. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AGZ by AG1: https://drinkagz.com/huberman David: https://davidprotein.com/huberman Eight Sleep: https://eightsleep.com/huberman Timestamps (0:00) David Sinclair (0:20) Longevity, Anti-Aging, Aging as a Disease (2:27) Causes of Aging; Epigenome & Genes (4:53) CD & Scratches Analogy, DNA, Silencing & Expressing Genes (6:44) Physical Appearance & Aging (7:36) Sponsor: David (8:54) Childhood Development & Aging, Horvath Clock, Accelerate Aging (11:30) Rates of Puberty & Aging, Growth Hormone (12:37) Body Size & Longevity; Epigenetics (13:07) Fasting, Calorie Restriction & Longevity, Sirtuins, Insulin & Glucose (16:31) Tool: Skip a Meal (17:07) Longer Fasts & Autophagy, “Deep Cleanse” (18:07) Sponsor: AGZ by AG1 (19:36) Fasting, Fluids, Electrolytes (20:16) Sirtuins, Glucose, mTOR & Fasting; Leucine, Tool: Pulsing Behaviors (24:24) Breaking a Fast, Tools: Do Your Best; Transitions (27:00) Sirtuins, NAD, NMN Supplementation (29:04) Sponsor: Eight Sleep (31:10) Iron & Senescent Cells; Personalize Medicine (32:40) Tool: Blood Markers, CRP (34:50) Tool: Aerobic & Resistance Exercise (35:55) Estrogen, Fasting & Fertility; Aging & Rejuvenation (38:20) Acknowledgements Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

In this bonus episode, Dr. Kahn sits down with Dr. William Hsu, Chief Medical Officer at L-Nutra (Prolon) and former Harvard Medical School faculty member, for a fascinating look at how fasting can help put Type 2 diabetes into remission. Dr. Hsu explains why muscle mass is crucial for managing diabetes — it's where glucose gets absorbed — and how the Fasting Mimicking Diet (just five days a month for six or more months) can lead to incredible results. The program not only supports blood sugar control but also helps preserve muscle and target belly fat, which is exactly what you want from healthy weight loss. Check out the programs mentioned in the episode:

"My ideas are often labelled as impossible, or useless, or both. Usually when people say that I'm on the right track."George Church is a geneticist, molecular engineer, and one of the pioneers of modern genomics. He's also someone who makes a habit of finding solutions to the seemingly impossible.Over the course of his career so far, George developed the first method for direct genomic sequencing, helped initiate the Human Genome Project, and founded the Personal Genome Project: making huge quantities of DNA data publicly available for research. Today, as a professor at Harvard Medical School and MIT, he's working on some of the most headline-grabbing - and controversial - science on the planet: from the so-called "de-extinction" of woolly mammoths, to growing transplant-suitable organs in pigs, to virus-proofing humans.When inspiration strikes, there seems to be little that will slow him down - even the fact that he has narcolepsy, the neurological disorder that causes sudden sleep attacks. In fact, as George tells Professor Jim Al-Khalili, some of his best ideas come in those moments between waking and sleep...Presented by Jim Al-Khalili Produced by Lucy Taylor for BBC Studios

Most people don't realize that what happens in the mouth can ripple through the whole body. The balance of the oral microbiome—the community of bacteria living in our mouths—can either protect us or trigger widespread inflammation that affects the heart, joints, and brain. Hidden dental infections or mercury fillings can quietly drive fatigue, autoimmune issues, or dementia—and fixing the mouth often helps the rest of the body heal, too. The good news is that with simple steps like eating whole foods (often removing gluten), cleaning the mouth well, and breathing through the nose, we can protect both our smile and our overall health. When we care for the mouth as part of the body, lasting wellness becomes possible from the inside out. In this episode, Dr. Todd LePine, Dr. Elizabeth Boham, James Nestor, and I talk about how a healthy mouth microbiome is a key to whole-body wellness. Dr. Todd LePine graduated from Dartmouth Medical School and is Board Certified in Internal Medicine, specializing in Integrative Functional Medicine. He is an Institute for Functional Medicine Certified Practitioner. Prior to joining The UltraWellness Center, he worked as a physician at Canyon Ranch in Lenox, MA, for 10 years. Dr. LePine's focus at The UltraWellness Center is to help his patients achieve optimal health and vitality by restoring the natural balance to both the mind and the body. His areas of interest include optimal aging, bio-detoxification, functional gastrointestinal health, systemic inflammation, autoimmune disorders, and the neurobiology of mood and cognitive disorders. Dr. Elizabeth Boham is Board Certified in Family Medicine from Albany Medical School, and she is an Institute for Functional Medicine Certified Practitioner and the Medical Director of The UltraWellness Center. Dr. Boham lectures on a variety of topics, including Women's Health and Breast Cancer Prevention, insulin resistance, heart health, weight control and allergies. She is on the faculty for the Institute for Functional Medicine. James Nestor is an author and journalist who has written for Scientific American, Outside, The New York Times, and more. His book, Breath: The New Science of a Lost Art, was an instant New York Times and London Sunday Times bestseller. Breath explores how the human species has lost the ability to breathe properly—and how to get it back. Breath spent 18 weeks on the New York Times bestseller list in the first year of release, and will be translated into more than 30 languages. Breath was awarded the Best General Nonfiction Book of 2020 by the American Society of Journalists and Authors, and was nominated for Best Science Book of 2021 by the Royal Society. Nestor has spoken at Stanford Medical School, Yale School of Medicine, Harvard Medical School, The United Nations, Global Classroom, and appeared on more than 60 radio and television shows, including Fresh Air with Terry Gross, the Joe Rogan Show, and more. He lives and breathes in San Francisco. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN to save 15%. Full-length episodes can be found here:The Functional Medicine Approach To Oral Health Getting Rid of Cold Sores and Canker Sores The Power Of Breath As Medicine